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Proteomics investigations rely on reference proteomes for the identification of proteins. These 
reference proteomes reflect the proteins that can be produced by an ideal organism, and so 
explicitly exclude protein isoforms that may be produced as a result of genetic mutation. In 
order to identify non-reference, or non-canonical, proteoforms the results of genomics analyses 
must be incorporated into the protein identification workflow. I developed such a 
proteogenomics workflow for the comprehensive identification and validation of non-
canonical proteins. This development was performed using MCF7 cells, a widely used in-vitro 
model of breast cancer, because it includes a large number of pathogenic mutations. The 
comprehensive proteogenomics analysis of MCF7 cells was performed using customized 
protein sequence database searches. In addition to confirming the protein forms of variants 
identified by next-generation sequencing, multiple novel proteoforms were identified and 
validated with synthetic isotopically-labeled standards. Peptides originating from single 
nucleotide variants, in-frame Insertion/Deletion, upstream open reading frames, transcripts in 
non-canonical reading frame, long non-coding RNA, transcripts with retained intron, exon 
extensions, novel exons, non-consensus splicing, variants not detected by next-generation 
sequencing, and novel isoforms were all identified and validated. Many of the proteins have 
previously been reported to play a role in tumor development, but many specific proteoforms 
are reported here for the first time. The results amply demonstrate that the reference proteome 
databases from UniProt, RefSeq and GENCODE widely underestimate the complexity of the 
oncoproteome space.  
The proteogenomics pipeline reported here was developed to be able to understand how cancer 
associated mutations affect the proteome, as many mutations do not lead to stable protein 
product. Furthermore, mutations may act through secondary routes and affect the regulation of 
which protein isoforms are produced, and so it is insufficient to limit the search to the direct 
protein analogues of the genetic mutation (i.e. altered peptide sequences produced by single-
nucleotide variants and insertion/deletion events). 
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In the last decades an unprecendented rate of improvement has been observed in the molecular 
analytical technolgies for nucleic acids and proteins. The high-throughput technologies for the 
analysis of nucleic acids and proteins have evolved in parallel but independently. 
Proteogenomics is a multi omics research area that integrates the results of mass spectrometry 
(MS) based proteomics with next-generation sequencing (NGS) based genomics, 
transcriptomics or translatomics to better characterize and understand cellular systems 1. In the 
past these methods were applied and studied independently to one another. Decreasing costs 
and improved ease-of-use (i.e. accessibility) has made it feasible to interrogate the same sample 
by multiple approaches. In proteogenomics the results of genome and RNA sequencing, gene 
expression, and protein expression are simultaenously investigated and integrated. The 
application of different molecular analysis methods on the same sample cohort is used to 
validate results and provide new insight that are not possible using any single technique. In 
proteogenomics customised protein sequence databases are generated using information from 
genome and RNA sequencing, which are then used to identify novel peptides that are not 
present in reference proteome databases 1. 
 
1.1. From genes to proteins 
In biology a gene is regarded as a unit of heredity that is passed from one generation to another. 
The genome is the complement of all genes that make up an organism. After the discovery of 
DNA as the genetic material 2 a gene was defined as a segment of DNA contained in a larger 
DNA strand that comprised a chromosome. The genome is the set of DNA strands on all the 
chromosomes in an individual. The genome is the blueprint of the organism, and can be said 
to contain the instructions in the form of protein coding and non-coding genes. The information 
flow from the gene begins with transcription, in which the genomic DNA is transcribed into 
RNA and finally translated into a protein, as depicted in Figure 1. The non-coding genes code 
for functional RNA molecules that are not translated into proteins. In the case of a protein-
coding gene the transcribed RNA molecule is known as a premature mRNA (pre-mRNA). The 
pre-mRNA molecule undergoes a process called splicing whereby some specific segments of 
the pre-RNA molecule are removed and the remaining are then concatenated together. The 
removed segments are known as introns and the retained segments are known as exons.  
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Figure 1. Steps of gene expression. 
 
The spliced RNA sequence is known as messenger RNA (mRNA). The mRNA sequence 
contains an Open Reading Frame (ORF) flanked by untranslated sequences (UTR). The UTR 
upstream of the ORF is known as 5’-UTR and the UTR downstream of the ORF is known as 
3’-UTR. During protein synthesis by ribosomes the mRNA is read three nucleotides at a time 
(codon) and, depending on the nucleotide code, a specific amino acid is incorporated into the 
growing protein chain (Figure 2A). The relationship between the codons and the incorporated 











Figure 2. Protein synthesis, the mRNA is read three nucleotides at a time. B) The genetic 
code translates the 3-nucleotide code into the identity of the amino acid. 
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The genetic code is the set of rules used by cells to translate the genetic sequence contained in 
the mRNA into a protein sequence. Each of the 20 amino acids are carried by specific transfer 
RNA (tRNA) molecules, which recognize a specific codon. Translation is carried out in the 
ribosomes where the codon on the mRNA is recognized by the anticodon on the tRNA, after 
which the amino acid carried by the tRNA is incorporated into the growing protein chain. 
During synthesis the protein is also folded into its conformation, the three-dimensional 
structure essential for its biological function.  
 
1.2. Genome sequencing 
Genome sequencing is the determination of the order of the DNA nucleotides in a genome. 
The genome of two individuals of a species is different due to the presence or the absence of 
DNA variants. Thus, for comparisons between the genomes of different individuals a reference 
genome is required. Individual genomes can then be compared against this reference genome. 
To provide such a standard reference genome for our own species the Human Genome Project 
(HGP) was launched in 1990 3. In 2004, HGP published a final version of the euchromatin 
region of the human genome 3–5. At the time, this was the highest quality vertebrate genome 
ever published. The source DNA for this project was sampled from several donors and 
analyzed by hierarchical shotgun assembly 4. In this approach, a set of large insert clones of 
100-200 kb each, covering the genome are generated 4. Shotgun sequencing is then performed 
on selected clones 4. The shotgun process generates fragments from random positions in the 
target molecule. The fragments from sequenced clones are then assembled into a linear 
sequence up to the total chromosome length 4. Following the success of the HGP the Genome 
Reference Consortium (GRC) was established to continuously maintain and improve the 
human genome 6. Besides the reference human genome the GRC also maintains and updates 
the mouse and zebrafish genomes 7. The data model of the reference genome released by GRC 
in the public domain is called an assembly 8. HGP and GRC provided the first comprehensive 
information on human gene structure which led to the growth of follow-up technologies such 
as genome wide association studies and genome wide gene expression profiling using 
microarrays 9. Later, the introduction of next generation sequencing (NGS) allowed sequencing 
of the whole genome of single individuals at ever decreasing cost (currently available for 
approximately 600 Euro at BGI-Europe) 10. 
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1.3. Genome annotation 
Genome annotation confers the structural and functional significance of every nucleotide in a 
genome. Since the sequencing of the human genome more than a decade ago, the process of 
annotation of the human genome is still ongoing. The result of genome sequencing is a DNA 
sequence containing a long string of the four nucleotides Adenine (A), Guanine (G), Cytosine 
(C) and Thymine (T). Genome annotation adds layers of information, including the precise 
location of genes, exons, introns, coding DNA sequence (CDS), and UTR, onto the DNA 
sequence 11. This is known as structural genome annotation. Functional annotation concerns 
the biological function, regulation and expression analysis of its structural elements. The use 
of the word genome annotation in this thesis specifically relates to its structural annotation.  
The reference human genome assembly released by GRC is annotated independently by the 
National Center of Biotechnology Information (NCBI) 12 and GENCODE 13. The NCBI 
Eukaryotic Genome Annotation Pipeline is an automated pipeline that produces structural 
annotations of coding and non-coding genes, transcripts and proteins on the finished and 
unfinished public genome assemblies 8. The annotation pipeline outputs the set of genes and 
their placement on the genome sequence. It provides content for various NCBI resources 
including Nucleotide, Protein, BLAST, Gene, and the Genome Data Viewer (GDV) 8. Core 
components of the pipeline are the alignment programs Splign 14, ProSplign 11, and Gnomon 
11, a gene prediction program combining information from experimental evidence and from ab 
initio models 11. The GENCODE Consortium aims to identify all gene features in the human 
genome using a combination of computational analysis, manual annotation and experimental 
validation 13. It provides refined annotations by integrating Ensembl automated predictions and 
the Human and Vertebrate Genome Analysis and Annotation (HAVANA) manual annotations 
13. The annotated gene models are divided into categories on the basis of their functional 
potential and the type of available supporting evidence 13.  The genes are categorized into 
protein-coding gene, long noncoding RNA (lncRNA) gene and pseudogenes 13. At the 
transcript level additional biotypes reflect functionality, for example, protein coding or subject 
to nonsense mediated decay (NMD) 13.  A status is assigned at both the gene and transcript 
level: known (represented in the HUGO Gene Nomenclature Committee (HGNC) database 
and RefSeq); novel (not currently represented in HGNC or RefSeq databases but supported by 
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transcript evidence or evidence from a paralogous or orthologous locus); or putative (supported 
by transcript evidence of lower confidence) 13. An example of a segment of the reference 
human genome (GRCh38) annotated by NCBI and GENCODE (Ensembl) is shown in Figure 
3. The annotation process is an ongoing effort thus each new release may update previous 
annotations. These updates can affect the number and structures of some genes, their 
corresponding transcripts and proteins.  
 
 
Figure 3. Genome annotations of a section of the human genome as seen in the Genome Data 
Viewer (GDV) from NCBI. The displayed region is from chr11: 72751835-72798640. The 
DNA sequence is shown at the top as a blue block. Annotations from NCBI release 109 and 
Ensembl (GENCODE) release 94 are shown in separate tracks. In each track, genes, transcripts 
and proteins are colored green, purple and red respectively. Exons are shown as blocks and 
introns as straight lines connecting exons. The annotation from the NCBI shows a single gene 
labeled STARD10, a single transcript labeled NM_006645.2 (purple line) and a single protein 
NP_006636.2 (red line). The Ensembl annotation contains two protein coding genes, Ensembl 
ids: ENSG00000186635 (ARAP1) and ENSG00000214530 (STARD10), the latter of which 
has multiple transcripts (purple lines) and multiple protein isoforms (red lines). Note: the start 
of ARAP1 is extended upstream in Ensembl annotation compared to NCBI annotation.     
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1.4.  Reference and variant sequences 
The assembled human genome provided by GRC represent a haploid assembly sampled from 
many individuals 6. The human genome (GRCh38), is a composite representation (a consensus) 
of the human genome 6. It is not a person’s genome. Variations in some regions of the human 
genome are so extreme that it is not possible to represent them in a single consensus sequence 
7. These regions are represented as alternate loci assembly units in the genome, for example 
highly variable histocompatibility gene segments on chromosome 6 8. Genome annotation 
pipelines utilized by NCBI and GENCODE provide the set of genes, transcript and proteins 
and their precise locations in the genome. This set of genes, transcripts and proteins are known 
as reference sequences. The reference sequences are the same for all individuals of a species. 
The genome of every individual is different due to the presence of DNA variants such as SNPs, 
block substitutions, homozygous indels, heterozygous indels, inversions, segment duplications 
and copy number variations 15. Furthermore the real genome of a person is diploid and is 
different than the genome of another person. The differences in the genome manifest at the 
transcript and the protein level, giving rise to molecules that will be different than the reference 
sequences. Thus, two individuals may produce a protein that is different in its primary 
sequence, or two individuals may produce a protein that are identical in their primary sequence 
but the encoding mRNA is different. The different sequences in different individuals are 
known as variant sequences. dbSNP is an NCBI resource of short variants (SNVs and InDels) 
16. As of dbSNP build 151, more than 660 million small variants have been reported in humans, 
out of which more than 381 million variants are localized in various genes of the human 
genome 17. This massive explosion in the numbers of variants identified in humans is largely 
due to the advent of NGS technologies.    
  
1.5. Next-generation sequencing 
First generation genetic sequencing technologies, such as capillary based Sanger sequencing 
and shotgun sequencing, were utilized for the generation of the sequence data of the HGP 3. 
The shotgun sequencing was performed on the insert clones and not on the whole genome, in 
order to eliminate the issue of long range misassembly and reduce the risk of short range 
misassembly 4. These assembly problems were perceived to be profound for the human 
genome due to the presence of almost 50% repeat sequences 4. In 2007, the introduction of 
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NGS technologies substantially lowered the cost of genetic sequencing. The application of 
NGS methods require the target DNA to be fragmented into smaller segments. These fragments 
are then fixed onto a medium and amplified by polymerase chain reaction (PCR) into colonies. 
The nucleotide sequences of the fragments in a colony are then determined using modified 
nucleotides. The modified nucleotides emit a light signal when integrated in to the growing 
chain, thus revealing their identity and the genome sequence. An image capture device is used 
to record the light signals, Figure 4.  
 
 
Figure 4. NGS technologies: template preparation, sequencing and data analysis. DNA is 
sheared by sonication or nebulisation to form fragments of 300–500 bp. Library amplification 




Different NGS platforms differ in the way the colonies are formed, amplified and how the 
nucleotide sequence is determined 18. High throughput is essential and is achieved by 
sequencing millions of colonies in parallel. The sequence data generated by the NGS platforms 
are referred to as reads, which is typically between 75 to 500 base pairs depending on the 
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platform. The ability to sequence massive amounts of DNA has enabled the investigation of 
genome sequences. Wang et al. utilized it to sequence the diploid genome of a person 10.  Yi 
et al. analyzed the exonic regions from 50 individuals for discovering adaptations to higher 
altitude 19. By converting mRNA into DNA one can evaluate gene expression at the genome 
scale and discover novel transcripts and splice isoforms 20.  
 
1.6. Exome sequencing 
The sequences corresponding to the exons in a genome is known as the exome. In humans, the 
exome comprises approximately 1% of the full genome sequence3. In whole exome sequencing 
(WES) the targets are the exons of all protein coding genes. Targeting only a subset of the 
genome in WES lowers the sequencing cost and simplifies the data analysis (compared to 
WGS). WES can be used for the identification of genetic variants that affect heritable 
phenotypes, which includes both pathological and natural variants 21–24. To selectively capture 
the exon sequences two types of technologies exist, solution-based and array-based exome 
capture. In solution-based exome capture the genome is fragmented and biotinylated probes 
are used to selectively capture and hybridize the exon sequences 25. The hybridized targets are 
captured using magnetic streptavidin beads and the untargeted sequences are washed away. In 
array-based capture the probes are bound on high-density microarrays 26. The probes 
selectively capture the exon sequences and the untargeted fragments are washed away. The 
captured targets are then amplified by PCR and sequenced by NGS  25. The reads generated by 
the NGS platforms are then aligned to the reference genome followed by variant calling to 
detect small mutations (SNVs and InDels)  in the sample 27.   
 
1.7. RNA-sequencing 
RNA-sequencing (RNA-seq) with NGS technology is used to identify and quantify RNA 
molecules. It is widely utilized for cataloging transcript species, such as mRNAs and lncRNAs, 
to determine the transcriptional structure of genes, and differential gene expression analysis, 
for example between normal vs disease state 20. Unlike Exome-seq where precise knowledge 
of target sequences (exons) is required RNA-seq can be performed without any prior 
knowledge of the target sequences (transcripts) 20. It can be applied for de-novo construction 
of the transcriptome for those species whose reference genome is not yet sequenced 28. It can 
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also be applied for the detection of DNA variants 29. In RNA-seq the target RNAs (for ex. poly-
A containing mRNAs) are extracted using poly-T oligo attached magnetic beads. The purified 
mRNAs are then fragmented into small pieces. The cleaved RNA fragments are then copied 
into cDNA sequences using reverse transcriptase.  The single stranded cDNA fragments are 
then copied into double stranded cDNA sequences. Adapters are then attached to the 
fragments. Each fragment with or without amplification is then sequenced by NGS. After 
sequencing, the resulting reads are either aligned to a reference genome or reference 
transcriptome, or assembled de-novo to construct the transcriptome map if the assembled 
genome is unavailable 18. 
  
1.8. LC-MS/MS based proteomics 
In mass spectrometry (MS) based proteomics the goal is to identify and quantify all proteins 
present in the sample. In the bottom-up proteomics approach the proteins are extracted and 
digested with a proteolytic enzyme such as trypsin. The resulting mixture of peptides is 
separated by Liquid Chromatography (LC) and injected into a mass spectrometer, where the 
peptides are ionized and accurate measurements made of the peptide’s mass and isotopic 
profile 30. Modern mass spectrometers are also able to isolate peptides (on the basis of the 
measured molecular mass) and then dissociate the isolated peptides into structurally 
informative fragments. This process, termed tandem mass spectrometry or MS/MS for short, 
provides the raw data used for the identification of proteins. The precursor ion mass (i.e. 
isolated and subject to MS/MS) and the masses of the structurally informative fragments are 
submitted to proteomics search engines 31. The search engines statistically match the 
experimental data (masses of precursor and MS/MS fragments) to theoretical data (masses of 
precursor and expected fragments) of the peptides predicted from a database of known protein 
sequences and assign a score for every match. The peptide with the highest scoring match 
between the experimental and theoretical data is reported as a Peptide Spectrum Match (PSM).  
Proteins are then inferred from the identified peptides, Figure 5. To evaluate the False 
Discovery Rate (FDR), a target decoy search strategy is utilized in which the same data is also 
searched against a database of decoy proteins. The decoy protein sequences are created from 
the target proteins by reversing or randomizing the amino acid sequences. The proportion of 
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PSMs in the decoy database to the total PSMs (target PSMs + decoy PSMs) above a score 
threshold is utilized to estimate the rate of false positives 32.  
The proteomics search engines utilized for protein identification require a database of protein 
sequences, usually this database is the reference proteome of the organism of the sample. A 
protein can only be identified if it is contained in the database. For many applications, 















Proteogenomics integrates the data generated from genome and transcriptome sequencing into 
the proteomics data analysis pipeline. The central idea in proteogenomics is to interrogate 
proteomics data using customized protein sequence databases that are derived from genome or 
transcriptome sequencing. Peptides identified from these custom databases but which are not 
part of the reference proteome can be utilized to discover novel genes, correct existing gene 
annotations and confirm the expression of variant proteins (e.g. resulting from mutation) 33 34.  
Initially proteogenomics was used for the correction of existing gene models 35. Lately it has 
emerged as a powerful tool in the study of cancer 36. Cancer is driven by genomic alterations 
that result in a series of genomic changes that include mutations, methylations, copy number 
aberrations and translocations 1. To understand the molecular changes associated with cancer 
deep genome sequencing has been performed, for example the International Cancer Genome 
Figure 5. Summary of protein identification by mass spectrometry. 
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Consortium and The Cancer Genome Atlas (TCGA) projects 37. It was later understood that 
the definition of the cancer proteome was also vital to link cancer genotypes to phenotypes. To 
accelerate the knowledge of the molecular basis of cancer through the application of 
quantitative, proteomic technologies the Clinical Proteomics Tumor Analysis Consortium 
(CPTAC) was launched under the auspices of the National Cancer Institute (NCI) 38. It carries 
out large scale proteome characterization of matched tumor samples which had undergone 
genome and transcriptome sequencing in the TCGA projects 38 . The complexity and high-
throughput nature of each omics technology is not amenable to manual interpretation. Thus, 
bioinformatics plays a vital role in proteogenomics for data integration and its interpretation 
39.  
Genetic mutations accumulate during cancer progression and change the proteome landscape 
by translation of variant proteins 40, aberrant proteins 41, alternative splice isoforms 42, upstream 
open reading frames (uORFs) 43,44, long non-coding RNAs (LncRNAs) 45 and novel protein 
coding sequences (CDS) 46. uORFs are protein translations from the 5’-UTR of the mRNA and 
always precede the natural start site in the mRNA 47,48. uORFs have been found to regulate the 
expression of the main ORF 49,50. Likewise, dORFs are translations from the 3’-UTR of the 
mRNA and always end after the natural stop site in the mRNA 48. LncRNAs are transcript 
classes that do not code for proteins because they do not contain a long open reading frame 51, 
nevertheless evidence for their active translation has been reported 48,52–54.  
The compact reference proteome databases from UniProt 55,  RefSeq 56, GENCODE 13 used to 
identify proteins in LC-MS/MS experiments only contain curated reference protein sequences, 
and so cannot be used to identify peptides from genomic variants or novel proteoforms. LC-
MS/MS analysis of a cancer proteome using such a reference protein database limits the 
analysis to proteins that are expressed by normal human cells. As such it under utilizes the 
sensitivity of MS methods to identify mutant or aberrant peptide signatures present in the 
sample that cannot be explained by a reference human proteome 57. 
Many specific germline mutations are strongly associated with disease and have been essential 
to our understanding of the molecular basis of many cancers 58–61. For example the 
identification of germline mutations in succinate dehydrogenase genes in patients with head 
and neck paragangliomas 62 and pheochromocytomas 63, inactivating mutations of fumarate 
hydratase in hereditary leiomyomas and type 2 papillary renal cell carcinoma syndrome 64, and 
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mutations in the isocitrate dehydrogenases genes in patients with Ollier disease 65  and low 
grade/secondary gliomas 66. 
In personalized proteogenomics sample specific mutation data is used to generate a patient-
and-sample-specific protein sequence database 57,67. Proteogenomics pipelines have been 
reported for the mutations and isoforms identified by NGS experiments 68. It should be noted 
that all of these types of genomic alterations may occur simultaneously, and protein sequences 
may also originate from supposedly non-coding transcripts and non-coding regions of protein 
coding transcripts 69,70. Furthermore there are many common protein modifications that may 
occur of biological origin (acetylation, deamidation, methylation, etc.), or that occur during the 
preparation of the samples (e.g. oxidation) or during the mass spectrometry analysis itself (loss 
of water, ammonia). When proteogenomics is used to identify novel proteoforms resulting 
from genomic mutation it is essential to first consider these common protein modifications, 
and to consider all types of mutation. The evidence level needed for the confident identification 
of novel proteoforms, especially those related to disease, necessarily exceeds that used for the 
routine identification of normal proteins.  
 
1.9.1. Databases for proteogenomics searches 
In proteogenomics the first step is the construction of customized protein sequence databases. 
The types of database utilized depend upon the goals of the proteogenomics experiment 71. If 
the goal is to discover protein variants, a database of variant proteins predicted from the 
genomic variants must be constructed 71. Likewise, if the goal is to identify novel protein splice 
isoforms, a database of novel proteoforms predicted from the reference genome or measured 
transcriptome can be generated. A database of ORFs from transcript sequences can be 
generated to discover uORFs, dORFs, alternate frame translations and translations from 
supposedly non-coding transcripts. A database of ORFs from gene sequences or full genome 
can be generated to discover intronic and novel CDS translations.    
 
1.9.2. Types of peptides in proteogenomics  
Peptides identified from the customized databases used in proteogenomics searches must be 
mapped onto the reference genome. By mapping these peptides onto the same genomic co-
ordinate system that is utilized to view NGS data the results can be placed in their genomic 
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context. All peptides in a proteogenomics search can be divided into two major groups, 
intragenic and intergenic peptides 71. Intragenic peptides map onto the annotated gene 
segments of the genome whereas intergenic peptides map onto the unannotated segments of 
the genome, Figure 6. The intragenic peptides can then be classified as protein-coding or non-
coding based on the biotypes of the genes onto which they map. The non-coding peptides map 
onto non-coding genes such as pseudogenes and lncRNA genes. Most peptides from an MS 
experiments map onto exons or between two or more exons (exon-spanning) of the protein 
coding genes. A small fraction can have a different origin, such as non-coding regions of 
protein coding genes (Intron, 5’-UTR, 3’-UTR). Others may map onto the protein coding 
transcripts in an alternate frame (Alt-frame). Intragenic peptides can also span the boundary of 
exons and introns (Exon-extension), or map onto unannotated alternative splice junctions 
(Exon-skipping). Peptides discovered from a personalized proteome (SNV and InDel) may 
map onto CDS regions of the gene. Finally, some peptides may map onto novel exons predicted 
by the RNA-seq data (novel isoforms). 
 
 
Figure 6. Types of peptides that can be identified in a proteogenomics experiment.    
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1.9.3. Proteogenomics mapping 
Search engines utilized in the identification of proteins from MS/MS spectra report identified 
proteins by their names or identifiers. The protein names or identifiers are extracted from the 
fasta headers of the sequences contained in the protein database supplied to the search engines. 
If gene level identification is desired a link between the identified protein and its encoding 
gene is established by matching the protein identifiers to the encoding genes. Peptides in 
proteogenomics searches may originate from reference proteins, SNVs, InDel, Exon-skipping, 
uORFs, altCDS, dORFs, Exon-extension, noncoding RNAs, novel isoforms, pseudogenes and 
novel CDS. Although all peptides identified in an LC-MS/MS experiment have a genomic 
origin: Genome  Gene  transcript  protein  peptide, search engines do not report 
peptides by their genomic co-ordinates. By mapping them onto a coordinate system that also 
enables the visualization of the corresponding genomic features one can learn about their 
genomic context. The coordinate system of choice is the reference genome of the organism. 
This coordinate system is extensively utilized for the display of NGS data, such as sequence 
reads, variants, and novel isoforms. Genome browsers such as the Integrative Genomics 
Viewer (IGV) and Genome Data Viewer (GDV) enable the visualization of genomic features 
alongside the NGS data. Thus, by mapping peptides onto the reference genome one can 
visualize them with their associated genomic features. The mapping procedure should report 
the result in a format that can be easily understood by the genome browsers. This is known as 
(proteo)genomics mapping. Currently, several tools exist that can be utilized for this purpose, 
such as PGx 72, Peppy 73, Proteogenomics Mapping Tool 74, Pepline 75, ProteoAnnotator 76, 
MSProGene 77, GalaxyP 78 and PoGo 79. Most available tools can be broadly divided into two 
groups: pipeline dependent and pipeline independent. The pipeline dependent tools such as 
Peppy and GalaxyP limit the users to a specific analysis pipeline, and thus a specific method 
for FDR, search engine etc... Although pipeline dependent tools can be user friendly in the 
sense they are designed with considerations to proteogenomics mapping, they limit the user’s 
freedom with regard to the bioinformatics options for peptide identification. Pipeline 
independent tools such as PoGo require the set of peptides as input, but generate the peptide 
co-ordinates in Browser Extensible Data (BED) file format, which is easily understood by 
genome browsers such as IGV and GDV.  
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1.9.4. Limitations with current proteogenomics mapping tools 
Although, many tools are available for mapping peptides to their genomic origin they have 
limitations in sensitivity and specificity 79 . BLAST is a powerful tool for alignment of query 
nucleic acid or protein sequences to a database of nucleic acids or proteins 80 . TBLASTN is 
one of the tools in the BLAST tool suite that can map a query protein sequence to a database 
of nucleic acids such as a reference transcriptome or reference genome. It can also be utilized 
to map peptides by customizing the TBLASTN search parameters for short sequences. 
TBLASTN suffers from sensitivity if the peptide sequence is too small and/or contains low 
sequence diversity. For example, the SNV peptide “LLLEEEQKEEEER” produced due to a 
mutation at chr10 position 3200020, cannot be mapped by TBLASTN (version 2.8.1) onto 
human RefSeq transcripts, genes or the full human genome. Furthermore, the TBLASTN 
output cannot be directly utilized in genome browsers and has to be converted to BED format 
or General Transfer Format (GTF).       
PoGo is another tool that can map reference and SNV peptides to their genomic co-ordinates. 
To perform mapping PoGo requires the peptides and associated PSMs as a text file, a reference 
annotation file (GTF), and a reference protein sequence file (FASTA). One of the output 
formats of PoGo is BED file format, which can be directly utilized in genome browsers for 
visualization. PoGo is a fast peptide mapper and can be successfully applied to map thousands 
of peptides directly onto the reference genome, and is also able to accommodate up to 2 SNVs 
on the peptides 79. Although PoGo is adept at mapping reference and SNV peptides onto the 
reference genome, it cannot map peptides produced due to Exon-skipping, InDel mutations, 
non-coding regions of protein coding transcripts, or non-coding transcripts. PoGo maps all 
peptides onto the reference proteome then transforms the peptide locations onto the reference 
genome without incorporating any knowledge of the detected SNVs. Even if the peptide has 
been generated from a VCF file of detected variants (NGS guided), PoGo does not utilizes this 
information and can map the SNV peptide to all possible genomic co-ordinates or reference 
proteins. For example, the SNV peptide “TNTFPLLEDEDDLFTDQKVK” of the gene 
WASHC2A and produced due to a mutation at chr10 position 50129923, was mapped by PoGo 
onto WASHC2A and WASHC2C. Both WASH genes are highly homologous with their 
corresponding UniProt proteins “Q641Q2” and “Q9Y4E1” sharing 97% sequence identity. 
The NGS data demonstrated that the mutation was present in WASHC2A and not in 
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WASHC2C. Specific RNA-seq reads were aligned onto the WASHC2A gene but not on the 
WASHC2C gene. Mapping the peptide with PoGo unnecessarily introduced ambiguity about 
its origin because it did not utilize all of the available information. In other words, despite NGS 
evidence that the peptide has a single genomic origin, event level classification of the peptide 






In this work computational methods for proteogenomics have been developed to identify and 
validate non-canonical proteins. The data for this project was generated from Exome-seq, 
RNA-seq and LC-MS/MS analysis of MCF7 cells.  
It is known that cancer is driven by mutations in the genome. Mutations accumulated during 
tumor development can alter the primary sequence and expression level of the mutated gene, 
and through dysregulation can affect the expression or other proteins. However the reference 
proteome databases used to identify proteins are curated to only include those proteins 
produced by normal cells, and thus cannot be utilized to identify those due to mutation. 
Proteogenomics analysis enables the analysis of such non-canonical proteins by creating 
customized protein sequence databases that include the mutant proteins, as well as novel 
protein isoforms that may result from dysregulation of protein expression.   
In the first part of my work I developed Python scripts to generate customized protein sequence 
databases from the reference genome, transcriptome and from variants identified in NGS 
experiments. These proteogenomics databases were then subsequently used to identify 
peptides from non-canonical proteins (i.e. those not included in the curated reference protein 
databases).  
In the second part of my work I focused on quality control of the non-canonical peptides. For 
example it is not uncommon that peptides will be confidently identified based on MS/MS 
spectra with a poor signal-to-noise-ratio. Such identifications have an increased risk of being 
a false positive because noise peaks may contribute to the identification. To guard against such 
false positives a dynamic noise level (DNL) algorithm was incorporated to remove peptides 
identified from spectra with poor signal quality.  
Peptides are frequently identified using a fraction of the peaks contained in the MS/MS 
spectrum, because the statistical match between experimental data and predicted MS/MS 
spectra is greater if the database search utilizes only the most common fragmentation channels 
for the MS/MS method. Although it is not necessary for the identification to use all high 
intensity fragment ions, the presence of non-annotated peaks increases the risk of false positive 
identifications. To further guard against the non-canonical peptides being false positive 
identifications an MS/MS spectrum annotation tool was developed to comprehensively 
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annotate the matched spectrum. The tool was utilized post database search to ensure that the 
other possible fragmentation channels could explain the non-annotated peaks. 
Non-canonical peptides identified through the proteogenomics analysis pipeline are best 
contextualized by mapping them on to the genome. In the third part of my work, I developed 
an algorithm to map these peptides onto the reference genome. The genomic mapping was 
utilized to assign context to the identified peptides and in their genomic classification. 
In the final part of my work I developed methods for the validation of the non-canonical 
peptides. Synthetic isotopically-labeled standards (SIS) of the non-canonical peptides were 
purchased; the SIS peptides were then added to the cell extracts and targeted proteomics 
experiments performed on the non-canonical peptides (endogenous and SIS). I wrote Python 
scripts to quantitatively compare the MS/MS spectra and elution profiles of the endogenous 
and SIS peptides. A two tier automated validation scheme was implemented in which the 
cosine similarity was utilized to compare the fragmentation patterns and elution profiles.  
The result of the proteogenomics searches, data quality control, genomic mapping, and 
validation, is a list of confident non-canonical peptides that can be classified in terms of the 
underlying genome. The development has been performed using the MCF7 breast cancer cell 







2.1. MCF7 cells 
In this project proteogenomics analysis of MCF7 cells line has been performed. Data from 
Exome-seq and shotgun proteomics of MCF7 cells were produced in-house whereas and the 
RNA-seq data on MCF7 cells was obtained from a public resource (Ion Community website 
81).  
   
2.2. Exome-seq 
The library was sequenced to mean 33x coverage using a Life Technologies Ion Proton 
sequencing platform (Ion Torrent, Life Technologies, Grand Island, NY) for NGS. Genomic 
DNA was extracted from MCF7 cells and the DNA concentration was measured using a Qubit 
system (Life Technologies). Each fragment library was constructed from 1 μg of DNA using 
the IonTargetSeq exome enrichment kit. The quality and the quantity of the amplified library 
was checked using an Agilent 2100 Bioanalyzer instrument with the Agilent High Sensitivity 
DNA Kit. A total of 500 ng of amplified, size-selected library DNA was used for exome 
enrichment: a probe hybridization reaction followed by recovery of the probe-hybridized DNA 
and amplification of the exome-enriched library. The exome-enriched library was analyzed on 
an Agilent 2100 Bioanalyzer instrument with the Agilent High Sensitivity DNA Kit and the 
dilution required for template preparation was determined. For sequencing an Ion PI 
Sequencing 200 kit (Ion Torrent, Life Technologies, Grand Island, NY) was used. After the 
Ion Proton run the data was analyzed in the Ion Torrent server (Ion Torrent, Life Technologies, 
Grand Island, NY), set for alignment to the reference human genome build 38.  The variants 
were called using the Variant Caller Plugin included in the Torrent suite. Variant analysis was 
restricted to variants occurring in exome regions.  
 
2.3. RNA-seq 
RNA-seq data of MCF7 cells was obtained from the Ion community website 81. Two data 
analysis pipelines, one using TopHat2 82  and the other using BWA MEM 83, were used. For 
both pipelines the reference human genome GRCh38 was used and variant calling was 
performed identically. In TopHat2 analysis the unmapped reads, generated from the first step, 
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were re-aligned using Bowtie2 84 . The reads mapped with Tophat2 and Bowtie2 were then 
merged using the Picard 85 command SamMerge. We applied the samtools 86 command rmdup 
on the merged file to remove PCR duplicates. Variant calling was performed by samtools 
command “mpileup”. A further filter with a Perl script (Vcf_filter, 2010, Ion Torrent System, 
modified by Nils Homer) was also performed. 
 
2.4. Genomic variants in MCF7 cells 
Variants identified in Exome-seq, RNA-seq and previously reported in the Catalogue Of 
Somatic Mutations In Cancer (COSMIC) 87 were obtained in Variant Call File (VCF) format 
and merged together into a single VCF file with VCFtools 88. The merged file contained the 





2.5.1. Reagents for LC-MS/MS 
Urea, Ammonium Bicarbonate (AmBic), Iodoacetamide (IAA), DL-dithiothreitol (DTT), 
bovine trypsin, water, acetonitrile (ACN), formic acid, ammonium hydroxide were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Lys-C was produced by Wako (Neuss, Germany). 
Complete mini EDTA-free Cocktail and PhosSTOP phosphatase inhibitor Cocktail in tablets 
were purchased from Roche (Basel, Switzerland). C18 and Reversed Phase, S (RPS) cartridges 
were purchased from Agilent Technologies (Santa Clara, CA, USA). 326 crude synthetic heavy 
stable isotope standard (SIS) peptides containing one C-terminal heavy Lysine (composition 
C12[-6]N14[-2]C13[6]N15[2]: +8 Da) or heavy Arginine (composition C12[-6]N14[-
4]C13[6]N15[4]: +10 Da) were purchased from JPT technologies (Berlin, Germany). 
 
2.5.2. Sample Preparation for LC-MS/MS  
MCF7 cells were lysed by sonication with an ultrasonic processor (Q125A, QSonica - 5 times 
50% power, 2 sec pulses, 40 J) in lysis buffer (8M urea, Complete mini EDTA-free Cocktail, 
PhosSTOP phosphatase inhibitor Cocktail and 50mM AmBic in MilliQ Water) and spinned 
down for 40 min at 21000 g. Supernatant was recovered in a clean eppendorf tube and the 
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protein concentration determined with a microBCA protein assay (Thermo Fisher Scientific). 
Reduction was performed using DTT at a final concentration of 4 mM during 25 min 
incubation at 56 °C. Alkylation was performed with 8 mM IAA, incubating at room 
temperature in the dark for 30 mins. Digestion was performed in two steps. Lys-C was added 
(1:75 enzyme/protein) and incubated for 4 hours at 37 °C. Trypsin was added at 1:100 
enzyme/protein after dilution to 2 M urea with 50 mM AmBic and incubated overnight at 37 
°C. In the morning the solution was acidified with 10 % formic acid in H2O until pH < 2. 
The resulting MCF7 proteolytic peptides were desalted and fractionated using an AssayMAP 
Bravo (Agilent Technologies) equipped with C18 and RPS cartridges, respectively. Peptide 
desalting was performed using the peptide cleanup V2 protocol. Briefly, C18 cartridges were 
primed with ACN, equilibrated with 50 µL of 0.1% Formic Acid, 100 µL of diluted samples 
were loaded at 5 µL/min. Two cup washes and a cartridge wash were performed with 50 µL 
of water 0.1% formic acid at 10 µL/min, followed by a stringent syringe wash with ACN and 
then peptides were eluted with 30 µL of 80% ACN and 0.1% formic acid at 5 µL/min. 
After desalting the proteolytic peptides were dried in vacuum, and resuspended in 10 mM 
NH4OH pH 10 solution for high pH fractionation. Two sets of fractions were generated for the 
proteogenomics discovery runs. For each run 150 µg of peptides were divided in seven 
fractions using different percentages of ACN in 10 mM aqueous NH4OH pH 10 for peptide 
elution. Specifically the elution solutions were Set A: 0%, 12.5%, 20%, 27.5%, 35%, 42.5%, 
70%; Set B: 0%, 12.5%, 17.5%, 22.5%, 27.5%, 32.5%, 70%. High pH fractionation was 
performed using the fractionation protocol V1.0. RPS cartridges were primed with 100 µL of 
ACN and equilibrated with 50 µL of 10 mM aqueous NH4OH pH 10. The peptide sample was 
loaded in 100 µL 10 mM NH4OH pH 10 at 5µL/min and the flow through was collected. A 
cartridge and cup wash were performed with 100 and 50 µL of the same high pH buffer, and 
fractions eluted with 35 µL plugs at 5 µL/min. All the fractions, including the flow through, 
were dried in vacuum and resuspended in 10% Formic Acid in water before individual LC-
MS/MS analysis. 
For the validation experiments 326 stable isotopically-labeled standard (SIS) peptides were 
individually resuspended in ACN/H2O/formic acid, ratio 50/49/1, and mixed in equimolar 
quantities using the “Reagent transfer” utility of the AssayMAP Bravo. Five sets of seven 
fractions were generated for the validation runs. In the first run, the MCF7 sample was 
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reanalyzed without addition of the SIS peptides. In the second, third and fourth runs the MCF7 
sample was spiked with the SIS peptides at three different concentrations (0.05, 1 and 20 fmol 
for every µg of tryptic digest). In the fifth and final run, the SIS equimolar peptide mix was 
analyzed separately. For each validation run high pH fractionation was performed on the 
AssayMAP Bravo using 0%, 12%, 18%, 24%, 30%, 36%, 80% of ACN in 10 mM aqueous 
NH4OH pH 10.  
 
2.5.3. LC-MS/MS analysis 
LC-MS/MS experiments were performed using an Easy-nLC 1000 (Thermo Scientific) 
coupled to an Orbitrap Fusion mass spectrometer (Thermo Scientific). Proteolytic peptides 
were separated using an EASY-spray C18 column (2 µm particle size, 75 µm x 50 cm, Thermo 
Fisher Scientific) equipped with a trap column (2 µm particle size, 75 µm x 2 cm Thermo 
Fisher Scientific). The eluents had the following composition, eluent A: H2O 0.1 % Formic 
Acid, and eluent B: ACN 0.1 % Formic Acid. Each peptide sample was loaded on to the column 
at 800 bar with 100 % A and peptides were eluted at 300 nl/min using a segmented gradient: 
5 % B for 5 min, 5 - 22 % B in 104 min, 22 - 32 % B in 15 min, 32 – 90 % B in 10 min, 90 % 
B for 15 min. The electrospray voltage was set at 2.2 kV and the ion transfer tube temperature 
at 275 °C.  
Data dependent tandem mass spectrometry was performed using top speed mode (3 sec max 
cycle time). The Full MS scan was acquired in the Orbitrap, m/z 350 to 1500, at 120,000 
resolution. The Automatic Gain Control (AGC, which controls the number of ions to ensure 
consistent high mass accuracy) target was set at 4e5 with 100 ms maximum injection time. 
Monoisotopic precursor selection and a dynamic exclusion of 60 s were adopted. Peptide ions 
with a charge state from +2 to +7 and an intensity greater than 5e3 counts were selected for 
high energy collision dissociation (HCD) using a normalized collision energy (NCE) of 35 % 
and a 1.6 m/z isolation window. MS/MS spectra were acquired in the ion trap mass analyzer 
with a rapid scan rate, 1e4 AGC target and 35 ms of maximum injection time. Data acquisition 
was performed in profile mode for the MS scans and in the centroid mode for MS/MS. 
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2.5.4. Reference proteome databases 
Reference human protein databases, in fasta file format, were obtained from UniProt (release 
September 2016), GENCODE (release 25), and RefSeq (release 78). Mapping files containing 
mapped protein sequences between GENCODE and RefSeq as well as between GENCODE 
and UniProt were obtained from GENCODE release 25. A reference protein sequence database 
was created by taking 82,636 non-redundant protein sequences from GENCODE. This protein 
set was extended with any UniProt protein sequence that had not been mapped onto 
GENCODE proteins. This included 1329 manually annotated “SwissProt” proteins and 610 
computationally predicted “TrEMBL” 89 protein sequences. Finally, we added 2643 manually 
annotated RefSeq protein sequences, which had not been mapped onto GENCODE. 
Computationally predicted RefSeq protein sequences were not added to the reference proteins 
to keep the number of reference sequences fairly small and complete. Finally, our reference 
protein database contained a total of 87218 non-redundant protein sequences. 
 
2.6. Data formats 
In this section the file formats utilized in this work are briefly described. Genome annotations 
were obtained in GTF and GFF3 format. The reference sequences (genes, transcripts and 
proteins) were obtained in FASTA format and the genomic co-ordinates of peptides were 
produced in BED file format. The genomic variants in MCF7 cells were obtained in VCF 
format.   
  
2.6.1.1.  Genome annotation and sequence file formats 
The reference human genome is released as a fasta file that contains the DNA sequences of all 
chromosomes, haplotypes, patches and scaffolds on the forward strand. Sequences are 
composed of 5 letters: Adenine (A), (Guanine) G, Cytosine (C), (Thymine) T and Unknown 
(N). The DNA sequence of the reverse strand is not included in the fasta file but can be inferred, 
since bases in the forward strand are complementary to the bases on the reverse strand (e.g. A 
pairs with T and G pairs with C). 
The annotations on the sequences in the fasta file are released in GTF or GFF3 format. The 
GTF or GFF3 format is a structured tab separated hierarchical feature file. This file format is 
extensively used to record genomic features such as gene, transcript, exon, CDS, start codon, 
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end codon and UTRs. A GTF file consists of 9 columns. The columns in the file are: seqname, 
source, feature, start, end, score, strand, frame and attribute. A line in the annotation file 
contains the chromosome (seqname), start position (start), end positon (end), and strand 
information for any feature localized in the genome. The chromosome can be one of autosomes 
(1 to 22), sex chromosomes (X and Y) and mitochondrial (M). The feature could be one of 
gene, transcript, exon, CDS, start codon, stop codon and UTR. The start and end values are 
positive integers which defines the inclusive range of nucleic acids that belong to a feature. 
The strand is either positive (+) or negative (-). The annotation file is hierarchically structured. 
A gene may have multiple transcripts and any transcript may have one or more exons. An exon 
may have a CDS if the transcript is protein coding.  
 
2.6.1.2. VCF file format 
A VCF file is used to record genomic variants. It is a structured tab separated file and contains 
8 columns. The columns in the VCF file are #CHROM, POS, ID, REF, ALT, QUAL, FILTER 
and INFO. Any variant detected by the variant calling programs is represented in a single line 
with its chromosome (#CHROM), position (POS), reference allele in the genome (REF) and 
the alternate allele (ALT) detected in the sample. The variants in the VCF file are always 
recorded in the forward strand.  
 
2.6.1.3. BED file format 
The BED format is a structured tab separated file that is used to record genomic features.  It 
can easily handle features that are distributed over multiple exons and can be loaded into any 
genome browser for visualization. A BED file consists of a single feature per line separated by 
tabs. Each line contains 3 to 12 columns. The 12 columns of the BED file are: chrom, 
chromStart, chromEnd, name, score, strand, thickStart, thickEnd, itemRGB, blockCount, 
clockSizes, blockStarts.   
1. chrom – name of the chromosome. 
2. chromStart – Start position of feature. The system is 0 based. 
3. chromEnd – End position of the feature. End position is not included in view. 
4. name – Display name of the feature. 
5. score –Score of the feature (between 0 to 1000). 
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6. strand – Strand defined as + or -. 
7. thickStart – Co-ordinate to start drawing co-ordinate as solid rectangle. 
8. thickEnd – Co-ordinate at which to stop drawing feature as solid line. 
9. itemRGB – An RGB color value for the feature. 
10. blockCount – The number of sub elements of the feature. 
11. blockSizes – The size of these sub-elements. 
12. blockStarts – The start coordinate of each sub-element. 
 
 
2.7. Algorithm development 
Python scripts were written for the generation of customized databases, application of a 
dynamic noise level (DNL) algorithm on MS/MS spectra, comprehensive annotation of 
MS/MS spectra, proteogenomics mapping of all classes of peptides, chromatogram extraction 
of endogenous and the synthetic stable isotope-labeled standard (SIS) peptides as well as 
comparisons of their fragmentation pattern and elution profiles. Besides the modules available 
in the Python standard library, the following packages were extensively utilized:  BioPython 
90, Pandas 91 , NumPy 92, SciPy 93, Pyteomics 94 and Matplotlib 95. In the following sections, 
the algorithms utilized for performing these tasks are briefly described.  
      
2.7.1. Extraction of reference sequences 
With the full genome and the annotation file it is possible to generate the full set of reference 
genes, transcripts and protein sequences. This might seem to be an unnecessary task since the 
annotation sources also provide these reference sequences. The reference genes, transcripts 
and protein sequences are the outputs of the genome annotation process. The utility of this task 
can be fully exploited when one seeks to perform sequence operations such as; producing a 
personalized genome, transcriptome and proteome. Sequences from the genome file can be 
extracted guided by their co-ordinates in the annotation file and customized databases for 
proteogenomics searches can be constructed. Programming languages such as Python have an 
extensive collection of modules for dealing with biological sequences. BioPython is one such 
package that can be used for the extraction, manipulation and translation of DNA sequences. 
Guided by the co-ordinates in the annotation file an in-silico transcription and translation can 
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be performed. To generalize this, let P be a protein that is produced from a transcript T of Gene 
G. Let’s assume transcript T has 3 exons, each containing a CDS. To obtain the full sequence 
of the protein coding gene G, the genomic co-ordinates of gene G in the annotation file can be 
utilized to extract the DNA sequence from the genome file (FASTA). If G is situated on the 
reverse strand of the DNA then the extracted gene sequence is reverse complemented. 
Automating the gene extraction process for all genes in the annotation file will result in a set 
of all gene sequences. If one wants to construct the spliced mRNA sequence of transcript T, 
then the DNA sequence of all three exons of transcript T are extracted from the genome file 
guided by their co-ordinates in the annotation file. If the transcript is located on the reverse 
strand then the extracted exon sequences are reverse complemented. The three exon sequences 
are then concatenated together in proper exon order to get the full length spliced mRNA 
sequence of transcript T. Automating the transcript extraction process for all transcripts in the 
annotation file will result in a set of all transcript sequences (reference transcriptome). If one 
wants to construct the full protein sequence P, the DNA sequence of each of the three CDSs 
on each of the three exons of transcript T are extracted guided by their co-ordinates in the 
annotation file. If the transcript is situated on the reverse strand, each of the extracted CDS 
sequences are reverse complemented. The CDS sequences from the exons are then 
concatenated together in proper CDS order to produce the full length CDS. The full length 
CDS is then translated into a full length protein P utilizing the proper genetic code. Repeating 
the protein extraction process for all protein coding transcripts in the annotation file will 
generate the full set of proteins (reference proteome). The described method for gene, transcript 
and protein extraction can be performed for any species whose genome has been sequenced 
and the corresponding annotation is available along with the genetic code for translation of 
nucleic acid sequences. The set of gene, transcript and protein sequences that can be extracted 
from the genome guided by their co-ordinates in the annotation file are referred to as reference 
sequences of the organism. The reference sequences are the same for all individuals of a 
species. The use of the terms reference genes, reference transcripts and reference proteins in 
the following sections would relate to these sequences that are accessible directly from the 
assembled genome (FASTA) and its corresponding annotation file (GTF or GFF3). 
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2.7.2. Generation of variant sequences 
In-house python scripts were utilized for the generation of variant proteins in FASTA format. 
To create a personalized proteome of a sample incorporating the variants identified by NGS, 
the VCF file can be utilized along with the annotation file (GTF or GFF3) and the genome file 
(FASTA). To generalize this, the example of generating a reference protein sequence P in the 
section above can be extended with the variant information in the VCF file. Let, V be a variant 
(SNP or InDel) located in the VCF file which causes amino acid changes in the encoded 
reference protein P. The variant V is stored in the VCF file with its chromosome (#CHROM), 
position on chromosome (POS), reference bases in the reference genome (REF) and alternate 
bases detected in the sample (ALT). Start and end co-ordinates of all three CDSs of protein P 
are scanned for the presence of variants in the VCF file. Reference CDS sequences of protein 
P that satisfy the condition: CDS start <= POS <= CDS end, are extracted. The CDS is then 
modified by the substitution of reference bases (REF) at position (POS) with alternate bases 
(ALT), and a variant CDS is generated. The variant CDS can now be utilized instead of the 
reference CDS to generate the full length CDS sequence, which upon translation will generate 
the full length variant protein. Repeating the variant protein generation process for all reference 
proteins in the annotation file, and utilizing all detected variants in the VCF file, will generate 
a set of variant proteins (personalized proteome).  
If more than one variant (mixed variants) were identified at a genomic location all possible 
variant CDSs were generated. If a protein contained more than one SNV they all appear on the 
same variant protein at different amino acid positions. If the variant amino acid in a protein is 
Arginine (R) or Lysine (K) it creates new tryptic sites. If more than one SNV occur in those 
proteins, the set of tryptic peptides generated when all SNVs are applied together will be 
different than the set of tryptic peptides when those SNVs are applied individually. For such 
cases, we also generated variant proteins in which all SNVs were individually applied. For 
example, if a protein contains two SNVs, one of them being R or K, a variant protein was 
generated with both SNVs appearing together on the same variant protein. Two other variant 
proteins were also generated in which the SNVs were individually applied. This approach 
provided all the tryptic peptides that could be obtained as a result of the two SNVs on the 
protein. Insertion or deletion mutations in the VCF file were applied one at a time, so for each 
insertion or deletion mutation separate variant protein sequences were generated. Thus, if a 
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protein had two insertion and two deletion mutations, four protein sequences were generated, 
one for each insertion and deletion mutation. 
 
 
2.7.3.  Generation of customized protein databases from the reference genome 
and transcriptome 
Python scripts were written to generate a database of novel exon-skipped proteins from the 
reference transcript structures in FASTA format.  An exon in the transcript was skipped if its 
frame of translation was the same as the subsequent exon, Figure 7. The exon-skipped 
transcript was then translated into an exon-skipped protein.  
 
 
Figure 7. An example of exon-skipping. The figure shows a transcript structure of a gene with 
5 exons (1 to 5) and 4 introns as straight blue lines connecting the exons. Exons that have the 
same frame of translation are shown in grey (exon 3 and exon 4). A novel exon-skipped 
isoform transcript sequence was generated by skipping exon 3, and splicing exon 2 to exon 4.    
 
Three transcript biotype specific databases were generated. GENCODE transcripts with 
biotypes protein coding or NMD, retained intron and long non-coding RNA were translated 
into ORFs in 3 frames (1, 2 and 3). Translation in frame 1 was conducted by taking all nucleic 
acids in the transcript sequence. Translation in frame 2 and 3 was done by removing one and 
two nucleic acids from the beginning of the transcript sequence, respectively. GENCODE gene 
and CDS sequences with 100 base pairs flanking sequences were extracted guided by their co-
ordinates in the GTF file. The extracted sequences were translated into ORFs in three frames.  
 
2.7.4.  Noise detection in the MS/MS spectra 
After the database search it is not uncommon that some peptides, even confidently identified 
peptides, are reported from spectra with poor signal-to-noise-ratio (SNR). When seeking to 
identify novel proteoforms it is incumbent to demand the highest data quality, in order to 
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minimize false positive identifications. In principal, such spectra can be filtered out through 
visual inspection but it cannot match the very high throughput of proteomics experiments. As 
part of an automated quality control of identified peptides a dynamic noise level algorithm 
(DNL) 96 was implemented in Python to filter out peptide spectrum matches that have low 
SNR. The DNL algorithm makes two assumptions about the MS/MS spectra: 1) in a good 
quality spectrum the signal peaks are of greater intensity than the noise peaks, and 2) there is 
at least one noise peak in all spectra 96. The steps of the DNL algorithm are:  
i) All peaks in the spectrum are sorted in order of increasing abundance Ii (i = 1, 2,… N).  
ii) The first peak in the sorted spectrum is assumed to be noise.  
iii) The SNR of the other peaks are calculated as the ratio of their intensity to the predicted 
peak intensity of a noise peak, which is predicted by scaling the abundance of the noise 
peak by a scaling factor (1 + α). Here the default setting of α was 0.5. 
iv) If the SNR of the second peak is greater than the minimum SNR threshold (SNRmin) the 
second peak is considered to be signal and the predicted noise level is set as the noise 
level for the entire MS/MS spectrum. If the SNR of the second peak is not greater than 
the SNRmin the algorithm scans from peaks 3 to N. For any peak k the previous k-1 peaks 
are considered noise. The noise level for peak k is calculated by fitting a linear regression 
to the intensities of the previous k-1 peaks. If the SNR for peak k exceeds SNRmin it is 
considered signal and that noise level is set as the noise level for the entire MS/MS 
spectrum.  
In this work the DNL algorithm was modified to not consider the second peak as signal. If the 
second peak was determined to be signal then the scaling factor α was increased by 0.1 until 
the second peak was determined to be noise.  
 
 
2.8. Comprehensive annotation of matched MS/MS spectra 
An additional quality control step consisted of assessing how many of the detected fragment 
ions could be explained by the identified peptide. The database search methods used for protein 
identification only use a fraction of the possible peptide fragmentation pathways, which is 
determined by the fragmentation method used, e.g. HCD generates primarily a, b, and y type 
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fragments, whereas electron transfer dissociation generates primarily c, and z type fragments, 

















The specification of the fragment ion series (determined by the MS/MS technique) during 
database search is performed to maintain statistical power: the inclusion of all possible 
fragmentation channels would increase the search space but decrease the specificity (the score 
distribution for the random matches is increased while the score for the correct match is 
unchanged). Accordingly, the MS/MS spectra from confidently identified peptides can contain 
high intensity but non-annotated fragment ion peaks that were not used for the identification. 
Although it is not necessary to annotate all high intensity peaks, annotating them increases the 
confidence in the identified peptide because more fragment ions can be explained. If the 
precursor ion is isolated with little or no interference from other co-eluting ions it is important 
that all high intensity fragment peaks can be rationalized. The MS/MS spectra used to identify 
peptides may contain fragment peaks that were not included in the database search, for example 
Figure 8. Peptide ion fragmentation channels in MS/MS. Double backbone cleavage can 
give rise to internal fragments, and cleavage of amino acid side chains can lead to d, v, 
and w fragment ions. 
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from immonium ions, internal fragments, and neutral losses of the peptide precursor. A python 
based spectrum annotation tool was developed to comprehensively annotate the matched 
spectrum. The tool was utilized post database search to investigate if unannotated peaks in 
MS/MS spectra could be explained by other fragment ion types, charge states and neutral 
losses. These quality control steps were developed to ensure all novel proteoforms were 
characterized by good signal-to-noise ratio MS/MS spectra, and in which the identification can 
be used to annotate all good signal-to-noise ratio peaks. 
 
2.8.1.  Proteogenomic mapping 
If the genomic co-ordinates of the peptides are tracked during the search (as in Peppy), peptide 
mapping is not required. If peptides are discovered from reference or customized databases, 
they need to be explained by mapping them onto the reference genome. Genome annotation 
systems at NCBI and GENCODE provide the co-ordinates of genes, transcripts, exon and CDS 
in GFF3 or GTF file format, respectively. These files do not contain the genomic co-ordinates 
of reference proteins, but they can be deduced from the genomic co-ordinates of its CDS. In 
this way, the peptide mapping problem can be traversed backwards where the peptide position 
on the protein is transformed into CDS co-ordinates. In the following sections algorithms 
implemented in python to map different types of peptides are shown. In all cases the algorithms 
use as inputs: genome annotations (in GTF or GFF3 format), a database of proteins (FASTA 
format) and input peptide sequences to be mapped (CSV format). 
 
2.8.1.1. Mapping reference peptides to the reference genome 
Genomic co-ordinates of peptides from reference proteins can be deduced by transforming the 
peptide position in the protein to its position on the full CDS. The peptide position on the full 
CDS can then transformed into its genomic co-ordinates. An algorithm to map peptides of the 
reference proteome to their genomic co-ordinates is described below. See Figure 9 and Figure 
10 for a graphical representation of peptide mapping in forward and reverse strand. 
Step 1: Let, PStart be the peptide start position on a protein and len be the length of the peptide. 
The peptide end position, PEnd, on the protein is given by: PStart + len -1.  
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Step 2: The peptide position onto the protein is transformed into its position on the full 
reference CDS. Let cdsStart be the start position of the peptide on the full CDS. Then, cdsStart 
can be computed with the formula:  
cdsStart = (PStart-1)*3 + frame of the first CDS of the protein + 1. 
The frame value (0, 1 or 2) for every CDS is encoded in the GTF. Frame value 0 indicates that 
the first base of the CDS is the first base of a codon, 1 indicates that the second base of the 
CDS is the first base of a codon, and 2 indicates that the third base of the CDS is the first base 
of a codon. Since each amino acid in the protein corresponds to a triplet of nucleic acids the 
end position of the peptide on the CDS, cdsEnd, can be computed as:  
cdsEnd = cdsStart + (3 * len ) - 1.  
Step 3. The CDS feature which contain the cdsStart and cdsEnd positions are extracted. This 
is done by extracting all CDS’s of the transcript and calculating their cumulative length until 
each CDS. These values are contained in the vector cumlen. The CDS on which the condition, 
cdsStart <= cumlen is satisfied for the first time is located. The peptide begins on this CDS 
feature which we refer to as cdsStartFeature. The subsequent CDS on which the condition 
cdsEnd<=cumlen is satisfied for the first time is located. The peptide ends on this CDS which 
we refer to as cdsEndFeature.  
Step 4: If the cdsStartFeature and cdsEndFeature are the same CDS then the peptide is located 
within a single CDS and is not exon-spanning. If cdsEndFeature is consecutive to 
cdsStartFeature the peptide spans CDSs of two exons: starting within the exon of 
cdsStartFeature and ending within the exon of cdsEndFeature. If any other CDS’s exist 
between cdsStartFeature and cdsEndFeature the peptide spans multiple exons. Once, the 
cdsStartFeature and cdsEndFeature are located the genomic start and end co-ordinate of the 
peptide can be calculated as follows: 
Genomic start =   Start of cdsStartFeature + cdsStart – cumlen before cdsStartFeature - 1 
Genomic end =    Start of cdsEndFeature + cdsEnd – cumlen before cdsEndFeature -1 
If the protein is on the reverse strand, 
Genomic start =   End of cdsStartFeature – (cdsStart – cumlen before cdsStartFeature) +1 
Genomic end =    End of cdsEndFeature – (cdsEnd – cumlen before cdsEndFeature) + 1. 
The deduced genomic start and end positions can be utilized to generate the peptide co-ordinate 
in BED file format. 
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Figure 9. Mapping reference peptides to the reference genome on the forward strand. The 
cdsStartFeature is shown as a blue box and the cdsEndFeature is shown as red box. The 
mapped genomic co-ordinate of the peptide is shown as a green block. The circled numbers 




Figure 10. Mapping reference peptides to the reference genome on the reverse strand. The 
cdsStartFeature is shown as a blue box and the cdsEndFeature is shown as a red box. The 
mapped genomic co-ordinate of the peptide is shown as a green block.  
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2.8.1.2. Mapping SNV peptides to the reference genome 
The algorithm discussed in section 2.8.1.1 can also be utilized to obtain genomic co-ordinates 
of SNV peptides if their reference proteins can be tracked. Instead of providing reference 
proteins (FASTA) a database of SNV proteins (FASTA) can be provided. An example fasta 
header of a SNV protein is shown below.  
>ENST00000629481.1_snp_4 chr19 Gene=ENSG00000239998.5 GN=LILRA2 Strand=+ 
54574349_T/C_49_ATC/ACC_I/T_snp 
The header of the SNV protein links it to reference Ensembl transcript ENST00000629481 of 
Gene LILRA2. Once the peptide location on the SNV protein is determined the genomic co-
ordinate of the reference transcript ENST00000629481 can be utilized to map the peptide, 
Figure 11. SNVs do not cause any change in the reference transcript length. Thus the mapping 
of peptides from SNVs can be treated in the same manner as the mapping of reference peptides 
to the reference genome.   
 
Figure 11. Mapping SNV peptides to the reference genome on the forward strand. The 
cdsStartFeature is shown as a blue box and the cdsEndFeature is shown as a red box. The 




2.8.1.3. Mapping exon-skipped peptides to the reference genome 
Exon-skipped proteins are generated from the reference transcript structures by skipping single 
or multiple exons. If the information regarding which exons were skipped from the reference 
transcripts is retrievable the mapping of the peptides is readily achieved. The algorithm 
described in section 2.8.1.1 can also be used for this task by modifying the inputs. Instead of 
reference annotation (GTF) and reference proteins (FASTA), an exon-skipped annotation 
(GTF) and a database of exon-skipped proteins (FASTA) are provided as inputs to the 
algorithm.  An example fasta header of an exon-skipped proteins is shown below. 
>ENST00000368216.8_NovIso_3 chr1 Gene=ENSG00000143303.11 GN=RRNAD1 
Strand=+ Skipping exon 3 
The header shows that the proteoform was generated by skipping exon 3 from the reference 
transcript ENST00000368216 of the RRNAD1 gene. In this case the GTF file needs to conform 
to the database of exon-skipped proteins. GTF file of exon-skipped isoform transcripts can be 
generated from the reference GTF file. For every exon-skipped protein in the fasta file a novel 
transcript feature can be generated by removing the exon and CDS features of the skipped exon 
from the reference transcript feature. For the proteoform example shown above, exon 3 and its 
CDS are removed from the reference transcript ENST00000368216. The modified GTF file, 
the fasta file of exon-skipped proteins and the peptides to map can then be submitted to the 
mapping algorithm described in section 2.8.1.1 to obtain genomic co-ordinates of the exon-




Figure 12. Mapping exon-skipped peptides to the reference genome. The cdsStartFeature is 
colored blue and the cdsEndFeature is colored red. The mapped genomic co-ordinate of the 
peptide is shown as a green block. 
 
   
 
2.8.1.4. Mapping peptides from 6 frame transcript sequences to the 
reference genome 
Proteogenomics searches can be conducted with three or six frame translated transcript 
sequences. Although most peptides from this type of search will have a reference protein origin 
some will not. These include peptides originating from (designated) non-coding regions of 
coding transcripts, peptides from non-coding transcripts and complement sequences of coding 
or non-coding transcripts. A fasta file of transcript sequences from which the peptides were 
discovered is required. This can be obtained from annotation resources such as NCBI or 
Ensembl or can be generated in-silico by utilizing the annotation file (GTF) and the full 
genome FASTA file. For in-silico generation all exons of a transcript are extracted from the 
full genome utilizing the co-ordinates of the exons in the annotation file. The exon sequences 
are concatenated in proper exon order. If the transcript is on the reverse strand the exon 
sequences are reverse complemented before concatenation. The transcript sequences can then 
be translated in three forward frames (1, 2 and 3). Translation in frame 1 is conducted by 
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utilizing all nucleic acids in the transcripts. Translations in frames 2 and 3 are conducted by 
utilizing all nucleic acids in the transcript except the first and the second base, respectively.  
If peptides need to be mapped on the complement sequences of transcripts then the reference 
annotation file can be appended with annotations for complement sequences. The protein 
translations from complement sequences need to be generated as well. This is easily achieved 
by reverse complementing the reference transcript sequences and translating them in frames 1, 
2 and 3. To generate annotations for complement sequences a copy of the reference annotation 
is generated. The strand information of all transcripts and its sub-features (exons and CDS) in 
the copied GTF file is reversed (+ to – and vice versa). The order of exons in also reversed. 
For example if a transcript had three exons on the forward strand, the strand is set to negative 
and the order of exons reversed in the copied GTF file. Exon number 1 is set to exon number 
3, and exon number 3 is set to exon number 1. The hierarchical order of exons (exon 1 followed 
by exon 2 and so on) in the copied GTF file is preserved after these changes. The modified 
GTF file can then be appended to the reference GTF file. After this step the modified mapping 
algorithm can be applied for peptide mapping. The inputs to the algorithm are the GTF file 
with reference and complement annotations, six-frame translated protein database and peptides 
to map, Figure 13.  
Step 1: Let PStart be the start position of a peptide on a proteoform and len be the length of 
the peptide. Then the peptide end position on the proteoform is: PEnd = PStart + len -1. 
Step 2: The peptide position on the proteoform is transformed into its position on the transcript. 
Let tStart be the start position of the peptide on the transcript, computed as: 
tStart  = (PStart-1)*3 + frame of the translated proteoform. 
The frame value (1, 2 or 3) for every proteoform is recorded while translating the transcript 
sequences. Since each amino acid in the proteoform corresponds to a triplet of nucleic acids 
the end position of the peptide on the transcript can be computed: 
tEnd = tStart + (3 * len) -1.  
Step 3: The Exon features that contain the tStart and tEnd positions are extracted. This is done 
by extracting the cumulative length until each exon of the transcript. The values are stored in 
a vector referred to as exon_cumlen. The exon on which the condition tStart <= exon_cumlen 
is satisfied for the first time is located. The peptide starts on this exon, referred to as 
exonStartFeature. The subsequent exon on which the condition tEnd<=exon_cumlen is 
 47 
satisfied for the first time is located. The peptide ends on this exon, referred to as 
exonEndFeature. 
Step 4: If the exonStartFeature and exonEndFeature are the same exon then the peptide is 
located within a single exon and is not exon-spanning. If exonEndFeature is consecutive to 
exonStartFeature the peptide spans two exons: starting within exonStartFeature and ending 
within the exonEndFeature. If any other exons exist between exonStartFeature and 
exonEndFeature then the peptide spans multiple exons. Once exonStartFeature and 
exonEndFeature are determined the genomic start and end co-ordinates of the peptide can be 
calculated as follows: 
Genomic start =   Start of exonStartFeature + tStart – cumlen before exonStartFeature – 1. 
Genomic end =    Start of exonEndFeature + tEnd – cumlen before exonEndFeature -1. 
If the protein is on the reverse strand, 
Genomic start =   End of exonStartFeature – (tStart – cumlen before exonStartFeature) +1. 
Genomic end =    End of exonEndFeature – (tEnd – cumlen before exonEndFeature) + 1. 
 
 
Figure 13. Mapping peptides from 6 frame transcripts to the reference genome. The 
exonStartFeature is colored blue and the exonEndFeature is colored red. The mapped genomic 
co-ordinate of the peptide is shown as a green block. 
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2.8.1.5. Mapping InDel peptides to the reference genome 
InDel mutations change the length of the encoded mRNA and thereby produce proteins whose 
lengths differ from the reference proteins. If the mutation is in-frame (addition or deletion of 
nucleotides in multiples of 3), it adds or removes amino acids into the encoded protein. If the 
mutation is out of frame (addition or deletion of nucleotides not in multiples of three) the 
protein’s primary sequence is modified and the protein’s length altered. If the mutation that 
generated the InDel peptide can be retrieved the genomic co-ordinates of the peptide can be 
deduced by modifying the mapping algorithm used to generate the cdsEnd co-ordinates in 
section 2.8.1.1 and supplying the reference GTF file, database of InDel proteins along with the 
peptide sequences to map. 
For example, a peptide “MVSAL-QQQQQQQR” was identified due to an in-frame deletion in 
protein TNRC6B. The fasta header of the in-frame deleted proteoform is shown below. 




The InDel protein is produced from reference transcript ENST00000454349 of TNRC6B. The 
fasta header shows the chromosome, gene id, gene name, strand and the mutation string. The 
mutation is in-frame deletion identified by the numbers of bases in the reference allele 
(REF)“TGCAGCAGCAGCAGCAGCAGCAGCAG” (26) and the alternate allele (ALT) 
“TGCAGCAGCAGCAGCAGCAGCAG” (23), respectively.  
The modified mapping uses:  
cdsEnd = cdsStart + (3 * len ) – 1 – (length of (ALT) –length of (REF)). 
After this modification the same algorithm described in section 2.8.1.1 can be applied to map 




Figure 14. Mapping peptides from InDel mutations to the reference genome. The 
cdsStartFeature is colored blue and the cdsEndFeature is colored red. The mapped genomic 
co-ordinate of the peptide is shown as a green block. 
 
 
2.8.1.6. Mapping peptides from six-frame gene sequences  
The gene sequences can be extracted from the full genome fasta file guided by their co-
ordinates in the GTF file. If peptide mapping is desired on the complement strands of genes 
the annotations for the complement sequences must be generated. This can be achieved by 
generating a copy of all reference gene annotations and reversing their strand information (+ 
to – and vice versa). All sequence (original and the copy) are then translated in three frames.  
Peptide positions are then computed on the translated proteoforms and transformed into 
genomic co-ordinates, Figure 15. Let PStart be the peptide start position in any proteoform 
and len be the length of the peptide. The peptide positions are then transformed into the 
genomic co-ordinates as follows: 
Genomic start = Start of the gene + frame of the proteoform + (PStart-1) * 3 - 1 
Genomic end = Genomic start + len*3 -1. 
For peptides mapped onto proteoforms in the negative strand, 
Genomic start = End of the gene – frame of the proteoform – (PStart-1) * 3 + 1 
Genomic end = Genomic start – len*3 +1. 
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Figure 15. Mapping peptides from six-frame gene sequences to the reference genome. The 




2.8.1.7. Mapping peptides from GNOMON predicted proteins to reference 
and alternate assemblies  
GNOMOM predicted proteins have two different genomic assembly origins. The reference 
(GRCh38) and the alternate (CHM1_1.1) assembly. Both of these assemblies and the 
corresponding annotations files generated by GNOMON are available from the NCBI. The 
algorithm described in section 2.8.1.1 can be used directly for mapping of peptides onto the 
GNOMON sequences by modifying the inputs. For reference assembly mapping the 
GNOMOM predicted proteins (FASTA) and the GNOMON predicted annotations (GFF3) 
from the reference assembly are provided as inputs. For alternate assembly mapping the 
GNOMOM predicted proteins (FASTA) and the GNOMON predicted annotations (GTF) from 
the alternate assembly are provided as inputs.  
 
2.8.1.8. Mapping peptides from 6 frame full genome searches  
The full genome (FASTA) contains all the chromosomes sequences in forward strand. Nucleic 
acid sequences of the complement strands can be generated by reverse complementing each 
chromosome sequence. All sequences can then be translated in three frames (1, 2 and 3). 
Peptide positions are then computed onto each translated proteoforms and transformed into 
genomic co-ordinates, Figure 16. Let PStart be the start position of a peptide onto a translated 
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chromosome and let len be the length of the peptide. Then the genomic co-ordinate of the 
peptide can be obtained as follows. 
Genomic start = frame of proteoform + (PStart-1)*3  
Genomic end = Genomic start + len*3 - 1  
If the proteoform was obtained from the reverse strand, 
Genomic end = length of chromosome - frame of proteoform – (PStart-1)*3 +1 
Genomic start = Genomic end – (len*3) +1. 
 
 
Figure 16. Mapping peptides from six-frame full genome searches. 
 
 
2.8.2. Generating peptide co-ordinates in BED format 
The sections above described the methods developed to obtain the genomic co-ordinates of 
peptides identified from the proteogenomics searches. All methods produced peptide co-
ordinates that were represented as: chromosome, peptide start position on the chromosome, 
and peptide end position on the chromosome. If the peptide was mapped onto the reverse strand 
of the DNA the peptide start co-ordinate was greater than the peptide end co-ordinate. 
Additional information is also available, such as; strand (forward or reverse), starting exon of 
the peptide (if any) and ending exon of the peptide (if any). These values are sufficient to 
represent the genomic co-ordinates of the peptides in BED file format, thus enabling the results 
to be loaded into any genome browser to visualize the location of the mapped peptides. The 
proteogenomics peptides were color coded into two groups: Ambiguous proteogenomics 
peptides (Black) and Unambiguous proteogenomics peptides (Red).  
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2.9. Validation of the non-canonical peptides  
Some of the non-canonical peptides identified by proteogenomics searches were selected for 
validation using synthetic 13C isotopically-labeled standard (SIS) peptides. The physical and 
chemical properties of the endogenous and SIS peptides are near identical, thus their 
chromatographic profiles and fragmentation patterns should be near identical. A similarity 
metric was used to validate the presence of the endogenous non-canonical peptides. A two-tier 
validation scheme was implemented in Python. Scripts were written for similarity 
computations between the fragmentation patterns (i.e. their MS/MS spectra) and elution 
profiles of the endogenous and SIS peptides.   
Tier1: The cosine similarity was used to quantitatively compare the fragment spectra from 
endogenous and SIS proteogenomic peptides. In-house python scripts were utilized for the 
following tasks. We first applied the DNL algorithm to the MS/MS spectra then annotated the 
signal peaks with fragment ion-types: a, b, y, internal ions (a-type, b-type) of length up to 10 
amino acids, and precursors with a maximum loss of 1 water and/or 1 ammonia. The maximum 
charge state for the fragments was set to 2+ if the precursor was doubly charged, otherwise it 
was limited to one less than the precursor charge. Fragment ion peaks matching un-fragmented 
precursors and its isotopes were removed from the spectra. If a peak could be matched to 
multiple fragment ions we annotated the peaks based on the following priority rule: N-terminus 
or C-terminus fragments > neutral losses from N-terminus or C-terminus fragments > internal 
fragments > neutral losses from internal fragments. If a peak matched to multiple annotations 
after priority based selection we selected the annotation that gave the lowest mass deviation. 
All matched fragment ions present in both the SIS and endogenous MS/MS spectra, above 
noise level, were utilized for determining MS/MS spectral similarity. The intensities of the 
fragment ion peaks were variance stabilized by square root transform and normalized to sum 
1000 before similarity computation. MS/MS spectral similarity was only computed if the 
endogenous and SIS MS/MS spectra contained at least 10 common fragment ions. Non-
canonical, proteogenomic peptides with a cosine similarity greater than 0.9 were considered 
validated at tier 1. 
Tier 2: The extracted ion chromatogram (EIC) of all tier 1 peptides, endogenous and SIS, were 
then examined to ensure their retention times were identical. MS raw files from validation runs 
were converted to .ms1 format with MSConvert (Proteowizard version 3.0.10051). MS1 scans 
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were centroided during conversion. The resulting peak lists were used for chromatogram 
extraction using in-house python scripts and a 10 ppm tolerance. Peptide identification time 
points were extracted from the Mascot 97 search results and the apex of peptide elution peaks 
calculated. Local intensity minimum time points before and after the elution apex were 
determined and used as the time range in which the endogenous and SIS peptide elution 
profiles were compared. If the computed elution profile time range was less than 15 seconds 
or more than 45 seconds we compared a 30 sec time window spanning the elution apex.  
The intensities of the peptides were estimated by summing the intensities of its monoisotopic, 
1C13 and 
2C13 peaks, and the similarity was computed between the endogenous and SIS peptide 
profiles. Next, a Savitzky Golay filter 98 was applied onto the summed extracted peaks and the 
similarity computed between the filtered endogenous and SIS peptide profiles. The peptide 
intensities within the time range were normalized to sum 1 before similarity computation. 
Peptides with a similarity score greater than 0.9 either in the raw or in the filtered profiles were 
selected for further processing. Next, we compared the Savitzky Golay filtered peak profiles 
of each individual isotope (monoisotopic, 1C13 and 
2C13) of the endogenous and SIS peptides. 
Peptides with a mean isotope profile similarity greater than 0.9 were selected for further 
processing. As a final filter the relative intensities of the isotopes were also compared; only 
those peptides whose isotope composition similarity was greater than 0.9 were considered 
validated at tier 2. 
 
2.10. Proteogenomics databases 
A database of 37,366 SNV proteins and a database of 106905 InDel proteins was created by 
utilizing all variants in the VCF file (see methods section generation of variant sequences for 
details).  Transcriptome fasta files were obtained from GENCODE release 25 and RefSeq 
release June 2016. A database of 187,036 novel splice isoforms was created by skipping single 
exons from the GENCODE mRNAs and “Non-sense mediated decay” (NMD) transcript 
structures. An exon in the GENCODE transcript was skipped if its frame of translation was the 
same as the subsequent exon. GENCODE transcripts with biotypes “protein coding” and NMD 
were translated into ORFs in 3 frames. NMD transcripts contain a premature stop site in its 
canonical reading frame and are targeted by the NMD pathway for degradation to prevent 
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production of truncated proteins 99. ORFs of length less than 10 were discarded and a database 
of 2,221,980 ORFs from protein coding transcripts was created.  
GENCODE gene and CDS sequences with 100 base pairs flanking sequences were translated 
into three frames and ORFs of length less than 20 were discarded. Two databases containing 
20,512,063 ORFs from genes and 1,706,623 ORFs from CDS sequences were created. 
GENCODE transcripts with biotype “long non-coding RNA” were translated in three frames 
and ORFs of length less than 20 were discarded. A database of 125590 ORFs from lncRNAs 
was created. GENCODE transcript sequences with biotype “retained intron” were translated 
in three frames and ORFs of length less than 50 were discarded. A database of 156169 ORFs 
from retained intron transcripts was created.  
A Fasta file of 316,902 GNOMON predicted human protein sequences was obtained from 
NCBI Annotation release 107. GNOMON is NCBI’s eukaryotic genome annotation pipeline. 
The fasta file contains model protein sequences based on experimental cDNA sequences and/or 
ab-initio models from the reference (GRCh38) and the alternate (CHM1_1.1) genome 
assemblies. Full length protein sequences in the GNOMON fasta file that were not present in 
the merged reference proteome were extracted and a smaller database of 69,136 GNOMON 
full length models was created. Henceforth, this database will be referred as GNOMON-small. 
Transcriptome fasta files from GENCODE containing 198,093 transcripts and RefSeq 
containing 176,426 transcripts were utilized for six-frame nucleic acid searches. The human 
genome fasta file was obtained from GENCODE release 23 and split into chunks with the help 
of a script (splitter.pl) from Matrix Science and utilized for six-frame nucleic acid search. All 
sequence databases were uploaded onto Mascot server 97 for database searches. 
 
2.11. Database searches 
2.11.1. Discovery searches 
The raw LC-MS/MS data from 14 in-depth proteomics investigations of MCF7 cells were 
converted to Mascot Generic Format (MGF) using Proteome Discoverer version 1.4 (Thermo 
Scientific). The MGF files were searched using Mascot server version 2.5. A total of 29 
discovery searches were performed, the details of which are reported in Table 1.  
10 searches were performed with different reference proteomes and search parameters (search 
numbers 1 to 10 in Table 1). 19 searches were performed with different proteogenomics 
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databases and search parameters (search numbers 11 to 29 in Table 1). Carbamidomethyl (C) 
was set as fixed modification and 0.6 Da fragment tolerance was used in all searches. Two 
searches (search numbers 3 & 4 in Table 1) with the merged reference proteome were 
conducted with 15 ppm precursor mass tolerance whereas it was set to 10 ppm in all other 
searches. Trypsin was set as the digestion enzyme in all searches except one search with the 
merged reference proteome where it was set to semi-trypsin (search number 5 in Table 1). A 
database of common Repository of Adventitious Proteins (cRAP) was obtained from The 
Global Proteome Machine (GPM) website and searched alongside all databases. Each of the 
proteogenomic databases was searched alongside the merged reference proteome database and 
cRAP database except for the 6 frame nucleic acid searches (search numbers 24,25,26,27 and 
29 in Table 1) because Mascot server version 2.5 did not allow amino acid database to be 
specified alongside nucleic acid databases. A maximum of 2 missed cleavages were allowed 
in all searches except for two proteogenomics searches where it was set to 0 (search numbers 
28 & 29 in Table 1). A total of 7 variable modifications were investigated for the reference 
proteome searches: Oxidation (M), Acetyl Protein (N-term), Deamidation (NQ), Carbamyl (N-
term), Gln->pyro-Glu (N-term Q), Glu->pyro-Glu (N-term E) and Ammonia-loss (N-term C). 
Because of the much larger search space for proteogenomic databases, these searches were 
performed using the 3 most common variable modifications, which were determined in a 
preliminary experiment using the reference proteome. The variable modifications used for the 
proteogenomic searches were Oxidation (M), Acetyl Protein (N-term), and Deamidation (NQ). 
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Table 1: Summary of database searches. Variable modifications are abbreviated as follows: 
Ac: Acetyl (Protein N-term), AL: Ammonia-loss (N-term C), Ca: Carbamyl (N-term), NQ: 
Deamidated (NQ), Gln: Gln->pyro-Glu (N-term Q), Glu: Glu->pyro-Glu (N-term E), Ox: 
Oxidation (M). Databases are abbreviated as follows: C: cRAP, MRP: merged reference 
proteome. Other abbreviations: 3F: 3 frame, 6F: 6 frame, PC: protein coding, MC: missed 
cleavages, Tol: peptide mass tolerance (ppm). 
 
# Databases used 
# 
Sequences # Residues Cleavage MC Variable Modifications Tol 
1  C, MRP 87334 32498123 Trypsin 2 Ac, Ox 10 
2  C, MRP 87334 32498123 Trypsin 2 Ac, NQ, Ox 10 
3  C, MRP 87334 32498123 Trypsin 2 Ac, Ox 15 
4  C, MRP 87334 32498123 Trypsin 2 Ac, AL, Ca, NQ, Gln, Ox 15 
5  C, MRP 87334 32498123 semiTrypsin 2 Ac, Ox 10 
6  C, GENCODE  proteome 94475 35226872 Trypsin 2 Ac, NQ, Ox 10 
7  C, UniProt  proteome 92633 36837450 Trypsin 2 Ac, NQ, Ox 10 
8  C, RefSeq  proteome 110502 74023435 Trypsin 2 Ac, Ox 10 
9  C, RefSeq  proteome 110502 74023435 Trypsin 2 Ac, NQ, Ox 10 
10  C, RefSeq  proteome 110502 74023435 Trypsin 2 Ac, NQ, Gln, Glu, Ox 10 
11  C, SNV  proteome, MRP 124700 75219935 Trypsin 2 Ac, Ox 10 
12  C, SNV  proteome, MRP 124700 75219935 Trypsin 2 Ac, NQ, Ox 10 
13  C, InDel  proteome, MRP 194239 100112565 Trypsin 2 Ac, Ox 10 
14  C, InDel  proteome, MRP 194239 100112565 Trypsin 2 Ac, NQ, Ox 10 
15  C, Exonskip  proteome, MRP 274370 270153356 Trypsin 2 Ac, Ox 10 
16  C, Exonskip  proteome, MRP 274370 270153356 Trypsin 2 Ac, NQ, Ox 10 
17  C, GNOMON  small, MRP 156470 87455704 Trypsin 2 Ac, Ox 10 
18 C,  PC  transcripts  ORFs  3F,  MRP 2309314 140406097 Trypsin 2 Ox 10 
19 CDS  extensions  ORFs  3F,  C, MRP 1706623 109281358 Trypsin 2 Ac, NQ, Ox 10 
20  C, LncRNA  ORFs  3F, MRP 212924 42228922 Trypsin 2 Ac, Ox 10 
21 C, Retained  intron  ORFs  3F, MRP 243503 47876774 Trypsin 2 Ac, Ox 10 
22 C, Retained  intron  ORFs  3F, MRP 243503 47876774 Trypsin 2 Ac, NQ, Ox 10 
23  C, GNOMON proteome, MRP 404236 237567077 Trypsin 2 Ac, Ox 10 
24 GENCODE  transcriptome  6F 1188558 588294950 Trypsin 2 Ox 10 
25 GENCODE  transcriptome  6F 1188558 588294950 Trypsin 2 NQ, Ox 10 
26 RefSeq  transcriptome  6F 1058556 1173530098 Trypsin 2 Ox 10 
27 RefSeq  transcriptome  6F 1058556 1173530098 Trypsin 2 NQ, Ox 10 
28  C, GENCODE  PC  genes  3F, MRP 20599397 870230701 Trypsin 0 Ox 10 





2.12.  Validation searches 
35 data files from the validation experiments, namely MCF7 cell extracts spiked with SIS 
peptides, were converted to MGF using MSConvert (Proteowizard version 3.0.10051). A 
proteogenomic database was created that contained the non-canonical peptides identified in 
the discovery proteogenomics searches. The MGF files of the 35 validation experiments were 
then searched on Mascot server against the merged reference proteome, proteogenomics 
database and cRAP database. Precursor and fragment mass tolerance were set to 15 ppm and 
0.6 Da, respectively. Carbamidomethyl (C) was set as fixed modification and Oxidation (M), 
Acetyl Protein (n-term), Deamidated (NQ), Carbamy (n-term), Gln->pyro-Glu (N-term Q), 
Label:13C(6)15N(2) (C-term K) and Label:13C(6)15N(4) (C-term R) were set as variable 
modifications. A maximum of 2 missed cleavages was allowed. 
 
2.13. Filtering proteogenomics peptides 
The results from the proteogenomics database searches were filtered at a significance threshold 
(p-value) of 0.05 and percolated to a False Discovery Rate (FDR) of 1% utilizing the “show 
percolator scores” option in Mascot. The FDR estimation was performed using a target decoy 
strategy inside Mascot using default settings. PSMs with percolated Mascot score below 13 
were removed. After utilizing Percolator 100 the Mascot score threshold 13 corresponded to a 
Mascot expectation score threshold of 0.05. All spectra identified in the discovery 
proteogenomics searches were collected. Python scripts were then utilized to filter the search 
results. We applied multiple filters to minimize false positive identifications. Specifically: 
i) All peptides identified in the reference database searches were removed. We 
filtered peptides against UniProt, RefSeq, GENCODE and cRAP databases by 
string search to ensure no non-canonical peptides could be mapped onto reference 
proteins or contaminants.  
ii) Peptides that differed with reference peptides only by Leucine/Isoleucine were 
removed.  
iii) Non-canonical peptides that contained a deamidation were removed if the peptide, 
after deamidation, could be mapped onto a reference protein. i.e. the non-
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canonical peptide and the peptide contained in a reference protein differed only by 
the deamidation (ND or QE) .  
iv) Non-canonical peptides with variable modifications Deamidation (NQ) and/or 
Oxidation (M) were removed if the corresponding unmodified peptide was not 
also identified.  
v) Non-canonical peptides identified from spectra whose precursor isolation 
exhibited greater than 70% interference were removed. Interference values for the 
precursor isolation were exported from Proteome Discoverer (version 1.4).     
vi) Only non-canonical peptides from MS/MS spectra that had at least 100 fragment 
peaks were retained. A dynamic noise level algorithm (DNL) was then applied to 
the MS/MS spectra 96. Fragment peaks with intensity above the noise level were 
regarded as signal peaks. Peptides from MS/MS spectra that had less than 8 signal 
peaks were also removed.  
vii) Only non-canonical peptides with length 10 to 40 amino acids were retained. 
viii) Non-canonical peptides originating from reference transcriptome and genome 
derived databases were also subjected to a local blastp (version 2.6.0+) 101 search 
against a combined database of the protein sequences from GENCODE, UniProt, 
RefSeq and cRAP proteomes. Non-canonical peptides originating from 
transcriptome and genome derived databases were removed if they could be 
aligned, using a maximum of two amino acid difference, with any protein 
sequence in the combined proteome. We noted that some of these peptides could 
not be aligned to reference proteins by blast search due to regions of low amino 
acid complexity, in this instance a string based search was used to establish if they 
matched. 
Some non-canonical peptides could be identified using multiple proteogenomics databases. We 
recorded the origin of all filtered peptides for all database searches and assigned a database to the 
peptide based on the following database priority rule: SNVs > InDel > Exonskip > GNOMON-
small > GENCODE protein coding transcripts > retained introns > CDS extensions > GENCODE 
protein coding genes > lncRNAs > GENCODE transcriptome > RefSeq transcriptome > 
GNOMON > human genome. 
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2.14. Proteogenomics mapping 
The “genomic context” of the non-canonical peptides was provided by mapping them onto the 
proteome, transcriptome and genome sequences using in-house python scripts. We obtained 
the genomic coordinates of the peptides in BED file format. Mapping was performed in a step-
wise manner in which peptides mapped at each level were classified and filtered out from the 
next mapping step as follows: 
i) Non-canonical peptides identified in the SNVs, InDel and Exonskip database 
searches were mapped onto their respective proteins. The peptide coordinates on the 
proteins were then converted to genomic coordinates utilizing the GENCODE release 
27 annotation file. Mapped peptides were classified as SNV-pep, InDel-pep and 
Exonskip-pep, respectively.    
ii) Peptides identified from GNOMON databases were mapped onto the GNOMON 
predicted protein sequences from NCBI annotation release 108. The peptide 
coordinates were converted to genomic coordinates using the GNOMON predicted 
annotation files from reference (ref_GRCh38.p7_gnomon_top_level.gff3) and 
alternate (alt_CHM1_1.1_gnomon_top_level.gff3) assemblies. Mapped peptides 
whose coordinates overlapped with any known protein-coding gene’s coordinates in 
the main annotation files from reference (ref_GRCh38.p7_top_level.gff3) and 
alternate (alt_CHM1_1.1_top_level.gff3) assemblies were classified as novel-
isoform-pep. Peptides mapping to locations containing non-coding genes in the main 
annotation files were classified as non-coding-pep, and peptides that mapped to 
locations that did not contain any known gene in the main annotation files were 
classified as novel-CDS-pep.    
iii) All remaining unclassified peptides were then mapped onto the GENCODE release 
27 transcriptome in 3 frames. Mapped peptides were classified as uORF-pep, altCDS-
pep and dORF-pep if they mapped onto the 5’-UTR, CDS and 3’-UTR regions of 
protein-coding or NMD transcripts, respectively. Peptides mapping onto the non-
coding RNAs were classified as non-coding-pep.  
iv) Peptides were then mapped onto the GENCODE release 27 gene sequences in 3 
frames. Peptides mapping onto protein coding genes were classified as intron-pep and 
exon-extension-pep if they originated from introns and exon-intron boundaries 
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respectively. Peptides mapping onto the non-coding genes were classified as non-
coding-pep.   
v) Next, peptides were mapped onto the transcriptome and gene sequences from NCBI 
annotation release 108 in 3 frames, and classified as mentioned in section iii) and iv) 
above for GENCODE annotation. 
vi) Peptides were then mapped onto the complement sequences of GENCODE 
transcriptome, GENCODE genes, RefSeq transcriptome and RefSeq genes, 
respectively. Mapped peptides were classified into novel-CDS-pep. 
vii) Finally, peptides were mapped onto the full human genome (GRCh38.p10) in 6 
frames. The peptide co-ordinates were converted to genomic coordinates. Peptides 
were classified into novel-CDS-pep if they mapped outside the annotated gene 
regions in GENCODE release 27 annotation file or RefSeq annotation from NCBI 
annotation release 108.   
During all mapping steps we accepted only those peptide co-ordinates that obeyed tryptic 
cleavage rule since all proteogenomics searches were conducted in tryptic mode. Finally, we 
performed gene based grouping of mapped proteogenomics peptides. Peptides that mapped to 
more than one gene, to multiple genomic coordinates, or were classified into more than one 
genomic context were reclassified into ambiguous-pep. 
 
 
2.15. Validation of the non-canonical peptides 
326 peptides corresponding to novel proteins identified with the discovery proteogenomics 
searches were selected for validation using SIS peptides. The peptides were selected on the 
basis of their length, 10-21 amino acids for easier synthesis, and without cysteine to avoid 
difficulties associated with Sulphur oxidation.  Five LC-MS/MS validation experiments were 
performed (see LC-MS/MS section for details). After database search (see section database 
searches for search parameters) the results were again percolated to a target FDR of 1%. We 
collected the spectra of the SIS and endogenous peptides from the discovery and validation 
searches. A two tier validation of selected peptides was then performed. In Tier 1, the cosine 
similarity was used to quantitatively compare the fragment spectra from the endogenous and 
SIS peptides. Peptides with a cosine similarity greater than 0.9 were considered validated at 
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tier 1. For Tier 2, the cosine similarity was used to compare the elution profiles and isotopic 
composition of SIS and endogenous peptides. Peptides that had a profile similarity and isotopic 




We performed a comprehensive proteogenomics analysis of MCF7 cells, a popular cancer cell-
line routinely utilized in cancer studies. We constructed customized databases utilizing variants 
from NGS data and COSMIC, GNOMON predicted proteins, reference transcriptome and the 
human genome. We first conducted extensive searches with reference proteomes from UniProt, 
GENCODE, RefSeq and a merged reference database. All peptides identified using the 
reference proteome databases were filtered out from the peptides identified using the 
proteogenomics searches. In this manner the subsequent data analysis focused exclusively on 
peptides due to novel (non-canonical) proteins. To guard against false positives we also 
conducted extensive QC checks of the identified non-canonical peptides. A sub-set of these 
peptides were then validated using synthetic isotopically-labeled standard (SIS) peptides. This 
study highlights the presence of proteoforms in MCF7 cells that are missed by proteome 
profiling experiments that only utilize reference proteomes and thus thereby underestimate the 
complexity of the oncoproteome. 
 
3.1. Application of the DNL algorithm  
MS/MS spectra contain noise. It is known that the database search method used to identify 
proteins can report confidently identified peptides from MS/MS spectra with poor signal-to-
noise. An example of such a PSM (peptide spectral match) with poor signal-to-noise is shown 
in Figure 17, in which the peaks colored red have been used for the peptide spectral match. 
When the focus of the study is the identification of novel proteoforms it is important to ensure 
that the identifications are not based on noise in the MS/MS spectra, as that would increase the 
chance of false positives. Low signal-to-noise spectra can be identified via visual inspection 
but given the throughput of modern proteomics experiments visual examination is highly 
unpractical. Instead we applied a dynamic noise level (DNL) algorithm 96 to the MS/MS 
spectra to remove PSMs with poor signal quality. After application of the DNL all MS/MS 
peaks in Figure 17 were found to fall below the noise level. 
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Figure 17. Example of a peptide identification resulting from an MS/MS spectrum with low 
S/N. The peptide “TKPGVQAALEVEVDRAEEGCQWGAPPTHGQAPHR”, charge 3+, m/z 
1226.993 was confidently identified by the Mascot search engine.   
     
 
3.2. Comprehensive annotation of matched MS/MS spectrum 
The database search of MS/MS spectra uses a set of predefined fragmentation channels. The 
choice of fragmentation channels depends on the tandem mass spectrometry method utilized 
to acquire the MS/MS spectra. For the collision induced dissociation method used here Mascot 
considers a, b and y fragment ions, including neutral loss of a single ammonia molecule. The 
maximum charge carried by the fragment ions is limited to 2+. These presets define the search 
space for the peptide-spectral-match.  
The MS/MS spectrum of the peptide “GTAAAAAAAAAAAAAKVPAK” is shown in Figure 
18. The peptide was mapped to the variant protein sequence of 60S ribosomal protein L14 
(RPL14). The variant protein contains three extra alanine residues (indicated in red above) 
when compared with the wild type RPL14 protein. Although the peptide sequence was 
identified with high confidence (Mascot Score: 43, expectation: 4.50E-05) many high intensity 
peaks in the spectrum remained unassigned (black peaks in Figure 18). Unassigned peaks in 
the MS/MS spectra increase the risk of false positive identifications, and so must be avoided 
when reporting novel proteins. To ensure all identifications of novel proteins could describe 
the majority of peaks present in the MS/MS spectra I developed a python based “spectrum 
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annotation tool” to comprehensively annotate the matched MS/MS spectrum. The annotation 
tool includes additional fragmentation channels not considered during the Mascot search. Note: 
the additional fragmentation channels were not used for identification, but to ensure the 
identifications could describe the MS/MS spectrum more completely. Figure 19 and Figure 20 
demonstrate that the inclusion of additional fragmentation channels increased the number of 





Figure 18. MS/MS spectra of the peptide "GTAAAAAAAAAAAAAKVPAK", charge 2+, 
m/z 812.465, as identified by Mascot (peaks used for identification indicated in red). 
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Figure 19. MS/MS spectra of the peptide "GTAAAAAAAAAAAAAKVPAK", charge 2+, 
m/z 812.465. Adding water loss as an additional fragmentation channel (indicated by **) led 
to additional peak matches, including b(3)**, b(4)**, b(5)**, b(6)**, b(7)**, b(8)**, b(9)** 
and b(10)**. Noise level (blue line) was determined by DNL. 
 
 
Figure 20. MS/MS spectra of the peptide "GTAAAAAAAAAAAAAKVPAK", charge 2+, 
m/z 812.465. Internal fragment ions (green peaks) were also utilized for annotation. Internal 
fragments are labeled by the start and end position of the fragment in the precursor peptide. 
Noise level (blue line) was determined by DNL. 
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3.3. Peptides from reference proteomes  
When we utilized GENCODE, UniProt and RefSeq as reference protein sequence databases 
(searches 6, 7 and 9 from Table 1) ~95 % of the peptides were identified by all three databases, 
Figure 21. Not including redundancies (i.e. the same peptide identified using different 
databases) we identified 270,741 spectra grouped into 97,144 peptides from all reference 
proteome searches (searches 1 to 10 in Table 1). ~25% of the 1,096,963 input spectra were 
assigned to peptides of the reference proteome. 52,548 spectra (~19 % of identified) were 
assigned to peptides with PTMs and 20,134 spectra (~7 % of identified) were assigned to 
peptides with unspecific cleavage. 
Using a standard RefSeq search with 2 variable modifications: Acetyl (N-term) and Oxidation 
(M) we could assign 199,133 MS/MS spectra. To ensure that MS/MS spectra from reference 
protein sequences were not mistakenly assigned as novel non-canonical proteins, we expanded 
the search to include different reference proteomes including common PTMs, artifacts and 
unspecific peptide cleavages. As a result, the number of MS/MS spectra that could be assigned 
to reference proteins was increased by almost 35%. 
 
Figure 21. Venn diagram of identified peptides (left) and identified spectra (right) from three 
common reference proteomes. The data is extracted from searches 6, 7 and 9 from Table 1. 
Only rank 1 peptide and spectra matches are shown.    
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3.4. Sensitivity of database search decreases with increasing database size 
The inclusion of all possible peptides contained in the transcriptome and genome greatly 
increase the size of the proteome database and thus decreases the statistical power of matching 
MS/MS spectra to peptides. To assess the severity of this effect for our analysis we determined 
how the protein identification rate was affected by database size. Searching the LC-MS/MS 
data against the merged reference proteome database resulted in 110,498 spectra 
unambiguously grouped onto 47,300 zero-missed-cleavage unmodified peptides (Figure 22). 
For the purposes of this database-size investigation we considered these identifications as 
representing 100% of the true reference spectra and reference peptides. The score distributions 
of these peptides, identified using different proteogenomics searches, are shown in Figure 22. 
Note: peptides with missed cleavages were not considered because searches with the ORF 
database derived from the gene sequence (search number 28 in Table 1) and the full human 
genome (search number 29 in Table 1) were conducted with 0 missed cleavages. A table 
summarizing peptides and spectra identified in all discovery searches is provided in online 
appendix 1. The number of peptides that could be consistently identified differed significantly 
for the proteome, transcriptome and genome derived databases. When we utilized the 
SNVs/InDel/Exonskip databases we recovered ~99% of the peptides identified using only the 
merged reference proteome. ~96% of peptides were recovered when the GNOMON database 
was used. Approximately, 91% of the peptides were recovered when utilizing the ORF 
database from CDS extensions and protein coding transcripts. ~74% of the peptides were 
recovered using an ORF database derived from gene sequences, whereas ~82% were recovered 
from a six-frame translated full transcriptome database. When the full human genome was 
searched in 6 frames just ~37 % of the peptides were recovered.  
The peptides that are present in the merged reference proteome are also present in the reference 
transcriptome and genome (except peptides spanning splice sites). Thus, at a constant 1% FDR 
fewer peptides could be identified when a larger database was utilized (even if all databases 
contained the peptides). As the peptide search space increases from proteome < transcriptome 
< genome the probability that an MS/MS spectrum will match to a random peptide sequence 
within the database increases, thus leading to an increased rate of false discovery. To mitigate 
the effect of larger database size and hence increased rate of false discovery, we conducted 
searches with proteogenomics databases targeting specific proteogenomics classes. For 
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example: to find peptides originating from transcripts with retained introns we utilized the 
retained intron transcripts from GENCODE and translated it in three frames, which accounts 




Figure 22. Percolated Mascot score distribution of unambiguous peptides (top) and spectra 
(bottom) with 0 missed cleavages identified in proteogenomics searches that were previously 
identified in the merged reference proteome search. The nucleic acid searches are indicated 
with an *. Search results were percolated to target FDR of 1% with p-value 0.05. Minimum 
Mascot score is 13. 
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3.5. Classification of non-canonical peptides identified by proteogenomics searches 
We collected all MS/MS spectra identified exclusively with the proteogenomics searches. This 
included 3760 spectra grouped into 3021 peptides. We subjected these identifications to 
extensive filtering to ensure all of these non-canonical peptides originated from high quality 
mass spectra and could not be assigned to reference peptides with common modifications. 
After this filtration step 1726 spectra remained that could be grouped into 1227 peptides. 
Annotated spectra of all filtered peptides are included in online appendix 8. We mapped the 
proteogenomic peptides onto the genome and classified all filtered peptides (Table 2). An 
example of the mapping of peptides onto the gene StAR related lipid transfer domain 
containing 10 (STARD10) is shown in Figure 23. The full list of filtered, classified peptides is 
provided in online appendix 2. Out of 1227 filtered peptides 55 could not be mapped onto the 
genome (Table 2). The genomic coordinates of all mapped 1172 peptides is provided in online 
appendix 3 & 4 in BED file format. 59 peptides were classified as ambiguous, which means 
they could be mapped onto multiple genomic coordinates, multiple genes or were classified 
into more than one genomic context. The remaining 1113 peptides were unambiguously 
classified into 11 different classes (Table 2). Of these, 203 peptides were classified as novel-
CDS-pep, which means they mapped onto genomic coordinates that are not currently 
annotated. The remaining 910 peptides were unambiguously grouped into 790 genes (Table 







Figure 23. Visualization of the genomic mapping of non-canonical peptides on to the gene 
STARD10. The peptides (shown in the “peptides” track) were identified from a GNOMON 
predicted protein model of STARD10 gene. The reference STARD10 gene, transcript 
(NM_006645.2) and protein (NP_006636.2) are shown in green, purple and red blocks, 
respectively, in the upper annotation track. The exons are shown as blocks and introns as lines 
connecting the blocks. The reference protein starts from exon 2 of the STARD10 transcript 
(note protein is on reverse strand). The GNOMON predicted model protein differs from the 
reference STARD10 protein, in that its N-terminal region has 77 additional amino acids. 
Proteogenomic mapping reveals that three of the peptides “R.KVASASAAASTLSEPPR.R”, 
“R.KVASASAAASTLSEPPRR.T”, and “K.VASASAAASTLSEPPR.R” map onto the 5’-
UTR region of the reference STARD10 mRNA. The results also demonstrate the presence of 
a novel exon predicted by GNOMON. “R.SAGAGSYGALANSAWGGPR.K” and 
“R.SAGAGSYGALANSAWGGPRK.V” map onto a region spanning the novel GNOMON 
exon and exon 2 of the reference STARD10 mRNA, and the peptide “MEEELALGPR.G” 






Table 2. All filtered non-canonical (proteogenomics) peptides classified by genomic context. 
 
 Discovery Validation 
Genomic context Peptides PSMs Genes Targeted Tier 1 Tier 2 
SNV-pep 295 630 219 152 143 108 
InDel-pep 36 46 35 6 3 1 
Exonskip-pep 8 9 8 0 0 0 
Novel-isoform-pep 45 108 36 17 16 12 
uORF-pep 87 126 72 27 17 5 
altCDS-pep 78 83 78 15 7 3 
dORF-pep 61 61 61 7 0 0 
Exon-extension-pep 30 35 29 1 1 1 
Intron-pep 98 100 97 8 1 0 
Non-coding-pep 172 187 169 32 9 2 
Novel-CDS-pep 203 213 0 46 4 1 
Ambiguous-pep 59 73 0 10 5 4 
Unmapped-pep 55 55 0 5 1 0 






3.6. Validation of non-canonical peptides identified by proteogenomics search 
A subset of the non-canonical peptides (length 10-21 amino acids, cysteine free) identified in 
the discovery searches were selected for validation. Isotopically labeled analogues of 326 
proteogenomic peptides were synthesized using heavy lysine or heavy arginine (stable 
isotopically labeled). Mixtures of the stable isotopically-labeled standard (SIS) peptide 
analogues were added to the MCF7 proteolytic peptides at 3 different concentrations and the 
samples analyzed by LC-MS/MS. The presence of endogenous proteogenomic peptides were 
validated on the basis of the similarity of the tandem mass spectra of the endogenous peptides 
with their isotopically labeled analogues (tier 1), and on the basis of matched retention times 
and elution profiles (tier 2). An example of a tier 1 and 2 validated peptide 
“R.SAGAGSYGALANSAWGGPR.K” from a GNOMON predicted novel isoform of 
STARD10 protein is shown in Figure 24 and Figure 25. Out of 326 peptides targeted for 
validation 19 of the isotopically labeled analogues were not detected (online appendix 2). 207 
peptides passed tier 1 validation, in which the MS/MS spectrum of the endogenous non-
canonical peptide scored at least 0.9 cosine similarity with that of the SIS validation standard 
(Table 2). A comparison of the MS/MS spectra from the endogenous peptides with their SIS 
analogues, for all non-canonical peptides that passed tier 1 validation is shown in online 
appendix 9. Of these, 137 peptides (66%) also passed tier 2 validation (Table 2). A comparison 
of the extracted ion chromatograms of the endogenous peptides and their SIS analogues, for 
all tier 2 validated non-canonical peptides, is available in inline appendix 10. In the following 
sections, we show examples of peptides identified from different genomic events. Peptides 
validated at tier 1 are shown in italic fonts and peptides validated also at tier 2 are shown in 




Figure 24. Annotated MS/MS spectra of the endogenous and SIS peptide of a novel isoform 
of STARD10. Peptide “R.SAGAGSYGALANSAWGGPR.K”, charge 2+ (left). Noise level 
(blue horizontal line) was determined by DNL. The N-terminal (a/b) and C-terminal (y) 
fragment ions are shown in red, internal fragments in green and un-fragmented precursors in 
orange. Ammonia loss is indicated with a * and water loss is shown with a $ sign. The spectra 
on the right show the MS/MS peaks selected for the similarity computation (top: endogenous 
peptide, bottom: SIS peptide). The intensities of the selected peaks were variance stabilized by 
square root transform and normalized to sum 1000 before similarity calculation. A total of 46 
common annotated peaks were compared. The peptide passed tier 1 validation with a similarity 























3.7. Peptides from variants identified by next-generation sequencing  
SNVs were the largest group of non-canonical peptides identified by the proteogenomics 
searches. 295 SNV peptides were identified with 630 PSMs (Table 2). We performed gene 
based grouping of the variant peptides and grouped the 295 peptides onto 219 protein coding 
genes. 152 SNV peptides were selected for validation using SIS peptides, of which 143 (94%) 
passed tier 1 validation and 108 (71%) also passed tier 2 validation. The largest number of 
SNV peptides was obtained from Plectin (PLEC) with 10 peptides and 28 spectra (online 
appendix 5). The SNV peptide “R.EQLQQEQALLEEIER.H”, variant amino acid shown in 
grey (Q/R), produced due to the variant “rs11136334” (Highest population MAF: 0.46) 102 was 




0C13: 875.419 m/z 
1C13: 875.920 m/z 
2C13: 876.422 m/z 
0C13: 880.423 m/z 
1C13: 880.925 m/z 
2C13: 881.426 m/z 
Figure 25. Extracted ion chromatograms of the endogenous peptide and the SIS peptide of a 
novel isoform of STARD10. Peptide “R.SAGAGSYGALANSAWGGPR.K”, charge 2+. The 
elution profiles were compared within the time window highlighted with a light blue box, and 
which corresponded to 42 MS scans. The peptide passed tier 2 validation with a profile 
similarity 0.99. Apex elution times for the SIS and endogenous peptides were both 85.6 
minutes. The MS/MS identification time points are shown with black vertical lines. Asterisks 
(*) indicate the MS/MS spectra have also been validated at tier 1 with a cosine similarity above 
0.9. The mass traces in the extracted ion chromatograms were extracted using an m/z tolerance 
of +/-10 ppm. 
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Figure 26. MS/MS spectra of the endogenous (top left) and SIS peptide (bottom left) from a 
common variant in PLEC gene. Peptide “R.EQLQQEQALLEEIER.H”, charge 3+. The noise 
level (blue horizontal line) was determined by DNL. The N-terminal (a/b) and C-terminal (y) 
fragment ions are shown in red, internal fragments (a-type, b-type) in green and un-fragmented 
precursors in orange. Ammonia loss is shown with a * and water loss is shown with a $ sign. 
The spectra on the right show the MS/MS peaks selected for the similarity computation (top: 
endogenous peptide, bottom: SIS peptide). The intensity of the selected peaks were variance 
stabilized by square root transform and normalized to sum 1000 before similarity computation. 
The intensities of 102 common annotated peaks were compared. The peptide passed tier 1 






Figure 27. Extracted ion chromatograms (EIC) of peptide “R.EQLQQEQALLEEIER.H”, 
charge 2+, in 5 validation runs. The elution profiles were compared within the time window 
highlighted with a light blue box. The peptide passed tier 2 validation with a profile similarity 
of 1.0. Apex elution times for the SIS and endogenous peptides were both 113.7 minutes. The 
MS/MS identification time points are shown with black vertical lines. Asterisks (*) indicate 
the MS/MS spectra have also been validated at tier 1 with a cosine similarity above 0.9. The 
top EIC (MCF7-light) shows the EIC of the endogenous peptide (MCF7-light) without any 
spike. The bottom EIC (Mix-heavy) shows the EIC of the SIS peptide in the SIS peptide 
mixture. The six EICs in between (0.05-light, 0.05-heavy, 1-light, 1-heavy, 20-light and 20-
heavy) show EIC’s of the light and heavy (SIS) peptide from the three validation experiments, 
in which the MCF7 tryptic digest was spiked with the SIS peptide mix at three different 
concentrations (0.05, 1 and 20 fmol for every µg of tryptic digest). The EICs of the SIS peptide 
in the validation runs are inverted for ease of comparison with the EIC’s of the endogenous 




A rare variant “rs2669761” (Highest population MAF: <0.01) 103  of WASH complex subunit 
2A (WASHC2A) was detected in the NGS experiments. The two peptides 
“K.TNTFPLLEDEDDLFTDQKVK.K”, and “K.TNTFPLLEDEDDLFTDQK.V”, were 
identified (variant amino acid in grey), the first of which passed tier 1 validation (Figure 28) 
and the second passed tier 1 and tier 2 validation (Figure 29 and Figure 30). 
 
 
Figure 28. MS/MS spectra of the endogenous (top left) and SIS peptide (bottom left) from a 
rare variant of WASHC2A. Peptide “K.TNTFPLLEDEDDLFTDQKVK.K”, charge 3+. Noise 
level (blue horizontal line) was determined by DNL. The N-terminal (a/b) and C-terminal (y) 
fragment ions are shown in red, internal fragments (a-type, b-type) in green and un-fragmented 
precursors in orange. Ammonia loss is shown with a * and water loss is shown with a $ sign. 
The spectra on the right show the MS/MS peaks selected for the similarity computation (top: 
endogenous peptide, bottom: SIS peptide). The intensity of the selected peaks were variance 
stabilized by square root transform and normalized to sum 100 before similarity computation. 
The intensities of 88 common annotated peaks were compared. The peptide passed tier 1 







Figure 29. MS/MS spectra of the endogenous (top left) and SIS peptide (bottom left) from a 
rare variant of WASHC2A. Peptide “K.TNTFPLLEDEDDLFTDQK.V”, charge 2+ (left). 
Noise level (blue horizontal line) was determined by DNL. The N-terminal (a/b) and C-
terminal (y) fragment ions are shown in red, internal fragments (a-type, b-type) in green and 
un-fragmented precursors in orange. Ammonia loss is shown with a * and water loss is shown 
with a $ sign. The spectra on the right show the MS/MS peaks selected for the similarity 
computation (top: endogenous peptide, bottom: SIS peptide). The intensity of the selected 
peaks were variance stabilized by square root transform and normalized to sum 100 before 
similarity computation. The intensities of 74 common annotated peaks were compared. The 




Figure 30. EICs of peptide “K.TNTFPLLEDEDDLFTDQK.V”, charge 2+, in 5 validation 
runs. The elution profiles were compared within the time window highlighted with a light blue 
box. The peptide passed tier 2 validation with a profile similarity of 0.99. Apex elution times 
for the SIS and endogenous peptides were identical in all validation runs. The MS/MS 
identification time points are shown with black vertical lines. Asterisks (*) indicate the MS/MS 
spectra have also been validated at tier 1 with a cosine similarity above 0.9. The top EIC shows 
the EIC of the endogenous peptide (MCF7-light) without any spike. The bottom EIC (Mix-
heavy) shows the EIC of the SIS peptide in the SIS peptide mixture. The six EICs in between 
(0.05-light, 0.05-heavy, 1-light, 1-heavy, 20-light and 20-heavy) show EIC’s of the light and 
heavy (SIS) peptide from the three validation experiments, in which the MCF7 tryptic digest 
was spiked with the SIS peptide mix at three different concentrations (0.05, 1 and 20 fmol for 
every µg of tryptic digest). The EICs of the SIS peptide in the validation runs are inverted for 




A total of 36 peptides from 46 PSMs were identified from insertion/deletion events. 6 InDel 
peptides were selected for validation, of which 3 passed tier 1 validation and 1 also passed tier 
2. An in-frame insertion variant “rs369485042” 104 of a trinucleotide repeat was detected in 
ribosomal protein L14 (RPL14) in its transcriptome. The corresponding peptides, each with 
three additional Alanine residues, “K.GTAAAAAAAAAAAAAKVPAK.K” and 
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“K.GTAAAAAAAAAAAAAKVPAKK.I” (additional amino acids in grey), were identified by 11 
PSMs and validated at tier 1 (Figure 31 and Figure 32).  
  
 
Figure 31. Annotated MS/MS spectra of the endogenous (top left) and SIS peptide (bottom 
left) of an in-frame insertion variant of ribosomal protein L14. Peptide 
“K.GTAAAAAAAAAAAAAKVPAK.K”, charge 3+. Noise level (blue horizontal line) was 
determined by DNL. The N-terminal (a/b) and C-terminal (y) fragment ions are shown in red, 
internal fragments (a-type, b-type) in green and un-fragmented precursors in orange. Ammonia 
loss is shown with a * and water loss is shown with a $ sign. The spectra on the right show the 
MS/MS peaks selected for the similarity computation (top: endogenous peptide, bottom: SIS 
peptide). The intensity of the selected peaks were variance stabilized by square root transform 
and normalized to sum 1000 before similarity computation. The intensities of 74 common 






Figure 32. Annotated MS/MS spectra of the endogenous (top left) and SIS peptide (bottom 
left) of an in-frame insertion variant of ribosomal protein L14. Peptide 
“K.GTAAAAAAAAAAAAAKVPAKK.I”, charge 4+. Noise level (blue horizontal line) was 
determined by DNL. The N-terminal (a/b) and C-terminal (y) fragment ions are shown in red, 
internal fragments (a-type, b-type) in green and un-fragmented precursors in orange. Ammonia 
loss is shown with a * and water loss is shown with a $ sign. The spectra on the right show the 
MS/MS peaks selected for the similarity computation (top: endogenous peptide, bottom: SIS 
peptide). The intensity of the selected peaks were variance stabilized by square root transform 
and normalized to sum 1000 before similarity computation. The intensities of 73 common 




An in-frame deletion event was detected in the gene Trinucleotide repeat containing 6B 
(TNRC6B) in the NGS experiments. The proteogenomic peptide “MVSAL-QQQQQQQR” 
with a deletion of the analogous Glutamine residue (indicated with a hyphen) was identified 




Figure 33. Annotated MS/MS spectra of the endogenous (top left) and SIS peptide (bottom 
left) of an in-frame deletion variant of TNRC6B. Peptide “MVSAL-QQQQQQQR”, charge 
2+. Noise level (blue horizontal line) was determined by DNL. The N-terminal (a/b) and C-
terminal (y) fragment ions are shown in red, internal fragments (a-type, b-type) in green and 
un-fragmented precursors in orange. Ammonia loss is shown with a * and water loss is shown 
with a $ sign. The spectra on the right show the MS/MS peaks selected for the similarity 
computation (top: endogenous peptide, bottom: SIS peptide). The intensity of the selected 
peaks were variance stabilized by square root transform and normalized to sum 1000 before 
similarity computation. The intensities of 45 common annotated peaks were compared. The 






Figure 34. EICs of peptide “MVSAL-QQQQQQQR”, charge 2+, in 5 validation runs. The 
elution profiles were compared within the time window highlighted with a light blue box. The 
peptide passed tier 2 validation with a profile similarity of 0.96. The MS/MS identification 
time points are shown with black vertical lines. Asterisks (*) indicate the MS/MS spectra have 
also been validated at tier 1 with a cosine similarity above 0.9. The top EIC (MCF7-light) 
shows the EIC of the endogenous peptide (MCF7-light) without any spike. The bottom EIC 
(Mix-heavy) shows the EIC of the SIS peptide in the SIS peptide mixture. The six EICs in 
between (0.05-light, 0.05-heavy, 1-light, 1-heavy, 20-light and 20-heavy) show EIC’s of the 
light and heavy (SIS) peptide from the three validation experiments, in which the MCF7 tryptic 
digest was spiked with the SIS peptide mix at three different concentrations (0.05, 1 and 20 
fmol for every µg of tryptic digest). The EICs of the SIS peptide in the validation runs are 
inverted for ease of comparison with the EIC’s of the endogenous peptide.  
 
 
3.8. Peptides from exon-skipping events 
We identified 8 peptides that were produced as a result of exon-skipping events (Table 2). 
None of the peptides were selected for validation because they did not meet the length 
requirements (10-21) for heavy peptide synthesis. The gene eukaryotic translation initiation 
factor 4 gamma 1 (EIF4G1) codes for a protein that is a component of the protein complex 
EIF4F. The peptide “MNKAPQSTGPPPAPSPGLPQHFYPSR.A” was identified from a novel 
isoform of EIF4G1, generated by the skipping of exon 3 from the protein coding transcript 
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“ENST00000342981”, Figure 35. The amino acids “MNKAPQSTGPPPAPSPGLPQ” derive 
from exon 2, and “HFYPSR" derive from exon 4. The peptide was identified in the discovery 
experiments with a single PSM corresponding to a missed cleavage, but was further supported 
by the identification of the terminal tryptic peptide “K.APQSTGPPPAPSPGLPQHFYPSR.A” 
with 3 PSMs in the validation experiments. To the authors’ knowledge, no known isoform has 
been reported that results from the splicing of exons 2 and 4 of transcript “ENST00000342981” 
(Figure 36). Thus, identification of this peptide indicates that a novel isoform of EIF4G1 is 
expressed in MCF7 cells, in which exon 3 of transcript “ENST00000342981” is skipped.  
 
 
Figure 35. Annotated MS/MS spectra of the endogenous peptide of the exon-skipped variant 
of EIF4F1 gene. Peptide “MNKAPQSTGPPPAPSPGLPQHFYPSR.A”, charge 3+. The noise 
level (blue horizontal line) was determined by DNL. The N-terminal (a/b) and C-terminal (y) 
fragment ions are shown in red, internal fragments are shown in green and un-fragmented 




























3.9. Peptides from non-coding regions of protein coding transcripts 
We identified 87 and 61 peptides that mapped onto the 5’-UTR, and 3’-UTR region of protein 
coding transcripts, respectively (Table 2). For example, the two peptides 
“R.GGAAPAGGGAEAGPGGGPGGAGGAAAK.A and “K.AGGAADMTDNIPLQPVR.Q” 
were identified from the 5’-UTR region of ATPase phospholipid transporting 9A (ATP9A), 
Figure 37. The amino acids GGAAPAGGGAEAGPGGGPGGAGGAAAKAGGAAD 
originate from the 5’-UTR region (indicated in grey here for clarity) and the amino acids 
MTDNIPLQPVR originate from the main ORF. The peptide 
Skipped Exon 
Figure 36. Visualization of exon skipped peptide “MNKAPQSTGPPPAPSPGLPQHFYPSR.A” 
on the EIF4G1 gene, Ensembl id: ENSG00000114867. The skipped exon, exon 3 of transcript 
ENST00000342981, is indicated. Green bars denote reference genes. Purple bars denote 
reference transcripts, and red bars reference proteins. Colored blocks represent exons, and lines 
introns. The genomic mapping of the exon skipped peptide sequence is shown in the bottom track 
as dark grey blocks. It can be seen that the peptide sequence span only the flanking exons; the 
peptide did not contain amino acids from the skipped exon. 
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“K.AGGAADMTDNIPLQPVR.Q” spanned the main ORF and the 5’-UTR region, and was 
validated at tier 1 and tier 2 (Figure 38 and Figure 39). 
 
 
Figure 37. The two peptides “R.GGAAPAGGGAEAGPGGGPGGAGGAAAK.A” and 
“K.AGGAADMTDNIPLQPVR.Q” map onto the 5’-UTR region of ATP9A mRNA 
ENST00000338821. The first peptide maps fully on to the 5’-UTR region of the transcript, 
whereas the second peptide maps onto the 5’-UTR region and the CDS coding for the first 11 
amino acids of ATP9A protein ENSP00000343481. Green bars denote reference genes. Purple 
bars denote reference transcripts, and red bars reference proteins. Colored blocks represent 






Figure 38. Annotated MS/MS spectra of the endogenous (top left) and SIS peptide (bottom 
left) that spans the main ORF and the 5’-UTR region of ATP9A. Peptide 
“K.AGGAADMTDNIPLQPVR.Q”, charge 2+. The N-terminal (a/b) and C-terminal (y) 
fragment ions are shown in red, internal fragments (a-type, b-type) in green and un-fragmented 
precursors in orange. Ammonia loss is shown with a * and water loss is shown with a $ sign. 
The spectra on the right show the MS/MS peaks selected for the similarity computation (top: 
endogenous peptide, bottom: SIS peptide). The intensities of the selected peaks were variance 
stabilized and normalized to sum 1000 before the similarity calculation. The intensities of 46 
common annotated peaks were compared. The peptide passed tier 1 validation with a similarity 
score of 0.96. 
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Figure 39. Extract ion chromatogram (EIC) of the endogenous and SIS peptide that spans the 
main ORF and the 5’-UTR region of ATP9A in 5 validation runs. Peptide 
“K.AGGAADMTDNIPLQPVR.Q”, charge 2+. The elution profiles were compared within the 
time window highlighted with a light blue box. The peptide passed tier 2 validation with a 
profile similarity of 0.98. Apex elution times for the SIS and endogenous peptides were 
identical in all validation runs. The MS/MS identification time points are shown with black 
vertical lines. Asterisks (*) indicate the MS/MS spectra have also been validated at tier 1 with 
a cosine similarity above 0.9. The top EIC (MCF7-light) shows the EIC of the endogenous 
peptide (MCF7-light) without any spike. The bottom EIC (Mix-heavy) shows the EIC of the 
SIS peptide in the SIS peptide mixture. The six EICs in between (0.05-light, 0.05-heavy, 1-
light, 1-heavy, 20-light and 20-heavy) show EIC’s of the light and heavy (SIS) peptide from 
the three validation experiments, in which the MCF7 tryptic digest was spiked with the SIS 
peptide mix at three different concentrations (0.05, 1 and 20 fmol for every µg of tryptic 
digest). The EICs of the SIS peptide in the validation runs are inverted for ease of comparison 





3.10. Peptides from alternate frame of protein coding transcripts 
We identified 78 peptides that mapped onto the CDS of protein coding transcripts but in a non-
canonical frame (Table 2). The gene keratin 8 (KRT8) is situated on the reverse strand of 
chromosome 12. A peptide “R.GLQLLQPHQLLQGR.G” was unambiguously mapped onto 
KRT8 gene and also validated at tiers 1 and tier 2 (Figure 40 and Figure 41). The reference 
protein is coded in the +3 frame of the protein-coding transcript “ENST00000552150” of 
KRT8 gene whereas this peptide exclusively mapped to the +2 frame (Figure 42). 
 
 
Figure 40. Annotated MS/MS spectra of the endogenous (top left) and SIS peptide (bottom 
left) from the alternate frame translation of KRT8 mRNA. Peptide 
“R.GLQLLQPHQLLQGR.G”, charge 3+. Noise level (blue horizontal line) was determined 
by DNL. The N-terminal (a/b) and C-terminal (y) fragment ions are shown in red, internal 
fragments (a-type, b-type) in green and un-fragmented precursors in orange. Ammonia loss is 
shown with a * and water loss is shown with a $ sign. The spectra on the right show the MS/MS 
peaks selected for the similarity computation (top: endogenous peptide, bottom: SIS peptide). 
The intensities of the selected peaks were variance stabilized by square root transform and 
normalized to sum 1000 before similarity computation. The intensities of 43 common 








Figure 41. Extracted ion chromatogram (EIC) of the endogenous and the SIS peptide from the 
alternate frame translation of KRT8 mRNA in five validation runs. Peptide 
“R.GLQLLQPHQLLQGR.G”, charge 3+. The elution profiles were compared within the time 
window highlighted with a light blue box. The peptide passed tier 2 validation with a profile 
similarity of 0.97. Apex elution times for the SIS and endogenous peptides were identical in 
all validation runs. The MS/MS identification time points are shown with black vertical lines. 
Asterisks (*) indicate the MS/MS spectra have also been validated at tier 1 with a cosine 
similarity above 0.9.The top EIC (MCF7-light) shows the EIC of the endogenous peptide 
(MCF7-light) without any spike. The bottom EIC (Mix-heavy) shows the EIC of the SIS 
peptide in the SIS peptide mixture. The six EICs in between (0.05-light, 0.05-heavy, 1-light, 
1-heavy, 20-light and 20-heavy) show EIC’s of the light and heavy (SIS) peptide from the three 
validation experiments, in which the MCF7 tryptic digest was spiked with the SIS peptide mix 
at three different concentrations (0.05, 1 and 20 fmol for every µg of tryptic digest). The EICs 
of the SIS peptide in the validation runs are inverted for ease of comparison with the EIC’s of 






Figure 42. Visualization of the peptide “R.GLQLLQPHQLLQGR.G on the KRT8 gene 
ENSG00000170421. The peptide maps onto the -1 frame of chromosome 12 whereas all 
reference KRT8 proteins are coded in the -2 frame (shown in six-frame translation track). 
Green bars denote reference genes. Purple bars denote reference transcripts, and red bars 
reference proteins. The locations of the peptide sequence identified by the proteogenomic 
search are shown in the bottom track (dark grey block). 
 
 
3.11. Peptides from non-coding transcripts and genes 
A total of 172 peptides from 187 spectra were identified from non-coding transcripts and genes 
(Table 2). This included transcripts with biotypes: retained intron, lncRNA, anti-sense, sense-
intronic, rRNA, TEC, and pseudogene transcripts. For example, GATA3 antisense RNA 1 
(GATA3-AS1) is a long non-coding RNA gene situated on the reverse strand of chromosome 
10. Two peptides “R.GAEVPGEAAPGAR.A” and “R.ARQPALPGELR.G” were identified 
from transcript “ENST00000355358” of GATA3-AS1 (Figure 43), the first of which satisfied 




Figure 43. Visualization of the peptides “R.GAEVPGEAAPGAR.A” and 
“R.ARQPALPGELR.G” on GATA3-AS1 long non-coding RNA. The peptides map onto the 
exon of GATA3-AS1 non-coding transcript ENST00000355358.  Green bars denote reference 
genes. Purple bars denote reference transcripts. Colored blocks represent exons, and lines 
introns. The locations of the peptide sequences identified by the proteogenomic search are 




Figure 44. Annotated MS/MS spectra of the endogenous (top left) and SIS peptide (bottom 
left) from long non-coding RNA gene GATA3-AS1. Peptide “R.GAEVPGEAAPGAR.A”, 
charge 2+. The N-terminal (a/b) and C-terminal (y) fragment ions are shown in red, internal 
fragments (a-type, b-type) in green and un-fragmented precursors in orange. Ammonia loss is 
shown with a * and water loss is shown with a $ sign. The spectra on the right show the MS/MS 
peaks selected for the similarity computation (top: endogenous peptide, bottom: SIS peptide). 
The intensities of the selected peaks were variance stabilized by square root transform and 
normalized to sum 1000 before similarity computation. The intensities of 23 common 




Figure 45. Extracted ion chromatogram (EIC) of the endogenous and SIS peptide from long 
non-coding RNA gene GATA3-AS1 in five validation runs. Peptide 
“R.GAEVPGEAAPGAR.A”, charge 2+. The elution profiles were compared within the time 
window highlighted with a light blue box. The peptide passed tier 2 validation with a profile 
similarity of 0.97. Apex elution times for the SIS and endogenous peptides were identical in 
all validation runs. The MS/MS identification time points are shown with black vertical lines. 
Asterisks (*) indicate the MS/MS spectra have also been validated at tier 1 with a cosine 
similarity above 0.9. The top EIC (MCF7-light) shows the EIC of the endogenous peptide 
(MCF7-light) without any spike. The bottom EIC (Mix-heavy) shows the EIC of the SIS 
peptide in the SIS peptide mixture. The six EICs in between (0.05-light, 0.05-heavy, 1-light, 
1-heavy, 20-light and 20-heavy) show EIC’s of the light and heavy (SIS) peptide from the three 
validation experiments, in which the MCF7 tryptic digest was spiked with the SIS peptide mix 
at three different concentrations (0.05, 1 and 20 fmol for every µg of tryptic digest). The EICs 
of the SIS peptide in the validation runs are inverted for ease of comparison with the EIC’s of 





The gene heterogeneous nuclear ribonucleoprotein L (HNRNPL) is situated on the reverse 
strand of chromosome 19. The missed cleavage peptide “R.QRQPPLLGDHPAEYGEGR.G” 
was identified with 5 PSMs from the retained intron transcript “ENST00000597731”. The 
peptide spans the boundary of exon 7 (amino acids shown in black) and intron 7-8 (shown in 
grey) of the protein-coding transcript “ENST00000221419” (Figure 46). Although the peptide 
was identified from the retained intron transcripts of HNRNPL, it could also be produced due 
to aberrant splicing of the protein-coding transcripts. For example, the splicing of pre-mRNA 
transcript “ENST00000221419” that retains intron 7-8 would lead to a larger protein 
containing the 37 extra amino acids originating from intron 7-8. The peptide was subsequently 
validated at tier 1 and tier 2 (Figure 47 and Figure 48). 
 
 
Figure 46. Visualization of peptide “R.QRQPPLLGDHPAEYGEGR.G” on the gene 
HNRNPL, Ensembl id: ENSG00000104824. The peptide maps onto the exons of retained-
intron-transcripts ENST00000597731 and ENST00000598985. The peptide also spans the 
boundary of exon and intron of protein coding transcripts ENST00000221419, 
ENST00000601449 and ENST00000600873. Green bars denote reference genes. Purple bars 
denote reference transcripts, and red bars reference proteins. Colored blocks represent exons, 
and lines introns. The locations of the peptide sequences identified by the proteogenomic 







Figure 47. Annotated MS/MS spectra of the endogenous (top left) and SIS peptide (bottom 
left) from the retained-intron transcript of HNRNPL. Peptide 
“R.QRQPPLLGDHPAEYGEGR.G”, charge 4+. The N-terminal (a/b) and C-terminal (y) 
fragment ions are shown in red, internal fragments (a-type, b-type) in green and un-fragmented 
precursors in orange. Ammonia loss is shown with a * and water loss is shown with a $ sign. 
The spectra on the right show the MS/MS peaks selected for the similarity computation (top: 
endogenous peptide, bottom: SIS peptide). The intensities of the selected peaks were variance 
stabilized by square root transform and normalized to sum 1000 before similarity computation. 
The intensities of 59 common annotated peaks were compared. The peptide passed tier 1 






Figure 48. Extracted ion chromatograms (EIC) of the endogenous and SIS peptide from the 
retained-intron transcript of HNRNPL gene in five validation runs. Peptide 
“R.QRQPPLLGDHPAEYGEGR.G”, charge 3+. The elution profiles were compared within 
the time window highlighted with a light blue box. The peptide passed tier 2 validation with a 
profile similarity score 0.94. Apex elution times for the SIS and endogenous peptides were 
identical in all validation runs. The MS/MS identification time points are shown with black 
vertical lines. Asterisks (*) indicate the MS/MS spectra have also been validated at tier 1 with 
a cosine similarity above 0.9. The top EIC (MCF7-light) shows the EIC of the endogenous 
peptide (MCF7-light) without any spike. The bottom EIC (Mix-heavy) shows the EIC of the 
SIS peptide in the SIS peptide mixture. The six EICs in between (0.05-light, 0.05-heavy, 1-
light, 1-heavy, 20-light and 20-heavy) show EIC’s of the light and heavy (SIS) peptide from 
the three validation experiments, in which the MCF7 tryptic digest was spiked with the SIS 
peptide mix at three different concentrations (0.05, 1 and 20 fmol for every µg of tryptic 
digest). The EICs of the SIS peptide in the validation runs are inverted for ease of comparison 









3.12. Peptides from introns and exon boundaries of protein coding genes 
A total of 98 peptides were identified from intronic regions and 30 peptides were identified 
from the exon-intron boundaries of protein coding genes (Table 2). The peptide 
“R.ASAAEGVGEPGASAGR.A” was identified with 2 PSMs from the gene WD repeat 
domain 26 (WDR26) in a search of ORFs generated from gene sequences (Figure 49). The 
peptide mapped on to the 5’-UTR region (amino acids “EGVGEPGASAGR.A” shown in black 
above) and the genomic region upstream of 5’-UTR (amino acids “R.ASAA” shown in grey 
above) of the protein coding transcript “ENST00000414423”. This peptide, validated at tier 1 
and tier 2, indicates that the first exon of transcript “ENST00000414423” is extended upstream 
and contains a CDS (Figure 50 and Figure 51).   
 
 
Figure 49. Peptide originating from upstream of exon 1 of WDR26. Visualization of peptide 
“R.ASAAEGVGEPGASAGR.A” on gene WDR26 (ENSG00000162923). The peptide spans 
the boundary of exon 1 of transcript ENST00000414423 and the genomic region upstream of 
exon 1. It also maps onto the intron of protein coding transcript ENST00000445239 (purple 
line) of WDR26. Green bars denote reference genes. Purple bars denote reference transcripts. 
The locations of the peptide sequences identified by the proteogenomic search are shown in 








Figure 50. Annotated MS/MS spectra of the endogenous (top left) and SIS peptide (bottom 
left) from the boundary of exon 1 and the genomic region upstream of exon 1 of WDR26. 
Peptide “R.ASAAEGVGEPGASAGR.A”, charge 2+. The N-terminal (a/b) and C-terminal (y) 
fragment ions are shown in red, internal fragments (a-type, b-type) in green and un-fragmented 
precursors in orange. Ammonia loss is shown with a * and water loss is shown with a $ sign. 
The spectra on the right show the MS/MS peaks selected for the similarity computation (top: 
endogenous peptide, bottom: SIS peptide). The intensities of the selected peaks were variance 
stabilized by square root transform and normalized to sum 1000 before similarity computation. 
The intensities of 49 common annotated peaks were compared. The peptide passed tier 1 








Figure 51. Extracted ion chromatograms of the endogenous and the SIS peptide from five 
validation runs. Peptide “R.ASAAEGVGEPGASAGR.A”, charge 2+. The elution profiles 
were compared within the time window highlighted with a light blue box. The peptide passed 
tier 2 validation with a profile similarity of 0.99. Apex elution times for the SIS and 
endogenous peptides were identical in all validation runs. The MS/MS identification time 
points are shown with black vertical lines. Asterisks (*) indicate the MS/MS spectra have also 
been validated at tier 1 with a cosine similarity above 0.9. The top EIC (MCF7-light) shows 
the EIC of the endogenous peptide (MCF7-light) without any spike. The bottom EIC (Mix-
heavy) shows the EIC of the SIS peptide in the SIS peptide mixture. The six EICs in between 
(0.05-light, 0.05-heavy, 1-light, 1-heavy, 20-light and 20-heavy) show EIC’s of the light and 
heavy (SIS) peptide from the three validation experiments, in which the MCF7 tryptic digest 
was spiked with the SIS peptide mix at three different concentrations (0.05, 1 and 20 fmol for 
every µg of tryptic digest).  
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3.13. Peptides from novel isoforms 
A total of 45 peptides were identified that were classified as novel isoforms of known protein 
coding genes (Table 2). 6 peptides from 46 PSMs were obtained from a GNOMON predicted 
model of STARD10 gene (online appendix 5). A blast search with the NCBI non-redundant 
protein sequences demonstrated that amino acids (78-368) of the protein model showed 100% 
similarity to reference human STARD10. Thus, the protein could represent an N-terminally 
extended (1-77) isoform of STARD10. All 6 non-canonical peptides of STARD10 identified 
by the proteogenomic analysis were mapped to this extended N-terminal region, Figure 52. 
Four of the peptides passed tier 1 and tier 2 validation, “R.SAGAGSYGALANSAWGGPR.K”, 
“R.SAGAGSYGALANSAWGGPRK.V”, “R.KVASASAAASTLSEPPR.R”, and 
“K.VASASAAASTLSEPPR.R”. Another passed tier 1 “R.KVASASAAASTLSEPPRR.T”. The 
final peptide was not included in the peptides selected for validation, “MEEELALGPR.G”. 
The identification and validation of 5 of these peptides indicates that a novel isoform of 
STARD10 is expressed by MCF7 cells. The tier 1 validation and tier 2 validation of one of the 




Figure 52. Mapping of the non-canonical peptides identified by the proteogenomic searches 
demonstrate the presence of an N-terminal extended form of STARD10. The peptides 
“R.KVASASAAASTLSEPPR.R”, “R.KVASASAAASTLSEPPRR.T” and 
“K.VASASAAASTLSEPPR.R” map onto the 5’-UTR region of protein coding transcripts of 
STARD10; the other three peptides “R.SAGAGSYGALANSAWGGPR.K”, 
“R.SAGAGSYGALANSAWGGPRK.V”, and “MEEELALGPR.G” do not map onto any 
reference transcripts. Green bars denote reference genes. Purple bars denote reference 
transcripts, and red bars proteins. Colored blocks represent exons, and lines introns. The 
locations of the peptide sequences identified by the proteogenomic search are shown in the 





Figure 53. Annotated MS/MS spectra of the endogenous (top left) and SIS peptide (bottom 
left) from the N-terminally extended isoform of STARD10. Peptide 
“K.VASASAAASTLSEPPR.R”, charge 2+. The N-terminal (a/b) and C-terminal (y) fragment 
ions are shown in red, internal fragments (a-type, b-type) in green and un-fragmented 
precursors in orange. Ammonia loss is shown with a * and water loss is shown with a $ sign. 
The spectra on the right show the MS/MS peaks selected for the similarity computation (top: 
endogenous peptide, bottom: SIS peptide). The intensities of the selected peaks were variance 
stabilized by square root transform and normalized to sum 1000 before similarity computation. 
The intensities of 47 common annotated peaks were compared. The peptide passed tier 1 




Figure 54. Extracted ion chromatograms (EIC) of the endogenous and SIS peptide from the 
N-terminal extended isoform of STARD10 in five validation runs. Peptide 
“K.VASASAAASTLSEPPR.R”, charge 2+. The elution profiles were compared within the 
time window highlighted with a light blue box. The peptide passed tier 2 validation with a 
profile similarity of 0.99. Apex elution times for the SIS and endogenous peptides were 
identical in all validation runs. The MS/MS identification time points are shown with black 
vertical lines. Asterisks (*) indicate the MS/MS spectra have also been validated at tier 1 with 
a cosine similarity above 0.9. The top EIC (MCF7-light) shows the EIC of the endogenous 
peptide (MCF7-light) without any spike. The bottom EIC (Mix-heavy) shows the EIC of the 
SIS peptide in the SIS peptide mixture. The six EICs in between (0.05-light, 0.05-heavy, 1-
light, 1-heavy, 20-light and 20-heavy) show EIC’s of the light and heavy (SIS) peptide from 
the three validation experiments, in which the MCF7 tryptic digest was spiked with the SIS 





The proteogenomics analysis provided evidence for the expression of a novel exon in Talin-1 
(TLN1). We detected 2 peptides from the GNOMON predicted protein model of TLN1 (Figure 
55). The peptides span exon 17, a novel exon, and exon 18 of transcript “ENST00000314888”. 
The first peptide, “R.SPPDSPTDALMQLAK.A”, spanned the novel exon (black) and exon 18 
(grey), and was validated at tier 1 and tier 2 (Figure 56 and Figure 57).  The other peptide, 
“R.QNLLQAAGNVGQASGELLQQIGESDTDPHFQICASR.G”, spanned exon 17 (grey) 
and the novel exon (black) but was too long to synthesize the isotopically labeled standard 
peptide needed for validation.  
A blast search with the NCBI non-redundant protein sequences demonstrated that this protein 
model has 100% sequence similarity to protein “AQN67632.1”, an isoform of TLN1. This 
isoform is not included in the reference protein datasets of RefSeq or GENCODE. The RNA-
seq data from NCBI includes a putative exonic region (black arrow in Figure 55) between exon 
17 and exon 18 of transcript “ENST00000314888”. Our RNA-seq data contains a significant 
number of reads in this region, aligned by both TopHat and BWA, Figure 58. The validated 
proteogenomics peptides and the RNA-seq data confirm the translation of the GNOMON 
predicted isoform of TLN1 in MCF7 cells.  
 
 
Figure 55. Visualization of the non-canonical peptides spanning a novel exon in the TLN1 
gene ENSG00000137076. The peptide “R.SPPDSPTDALMQLAK.A” spans the novel exon 
and exon 18; the peptide “R.QNLLQAAGNVGQASGELLQQIGESDTDPHFQICASR.G” 
spans exon 17 and the novel exon. RNA-seq exon coverage from the NCBI includes a putative 
exonic region (black arrow) between exons 17 and 18. Expression of the novel exon in MCF7 
cells would cause the insertion of 17 extra amino acids “ICASRGAGVRSPPDSPT” at 
position 666 in reference protein ENSP00000316029. The tryptic parts of this insertion are 
included in the peptides identified by the proteogenomics search (indicated in bold text). Green 
bars denote reference genes. Purple bars denote reference transcripts, and red bars proteins. 
Colored blocks represent exons, and lines introns. The locations of the peptide sequences 
identified by the proteogenomic search are shown in the bottom track (dark grey blocks 
overlapping with exons 17, 18 and the novel exon).  
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Figure 56. Annotated MS/MS spectra of the endogenous (top left) and SIS peptide (bottom 
left) from the novel isoform of TLN1. Peptide “R.SPPDSPTDALMQLAK.A”, charge 2+. The 
N-terminal (a/b) and C-terminal (y) fragment ions are shown in red, internal fragments (a-type, 
b-type) in green and un-fragmented precursors in orange. Ammonia loss is shown with a * and 
water loss is shown with a $ sign. The spectra on the right show the MS/MS peaks selected for 
the similarity computation (top: endogenous peptide, bottom: SIS peptide). The intensities of 
the selected peaks were variance stabilized by square root transform and normalized to sum 
1000 before similarity computation. The intensities of 57 common annotated peaks were 






Figure 57. Extracted ion chromatograms (EIC) of endogenous and SIS peptides from a novel 
isoform of TLN1 in five validation runs. Peptide “R.SPPDSPTDALMQLAK.A”, charge 2+. 
The elution profiles were compared within the time window highlighted with a light blue box. 
The peptide passed tier 2 validation with a profile similarity of 0.99. Apex elution times for 
the SIS and endogenous peptides were near identical in all validation runs. The MS/MS 
identification time points are shown with black vertical lines. Asterisks (*) indicate the MS/MS 
spectra have also been validated at tier 1 with a cosine similarity above 0.9. The top EIC 
(MCF7-light) shows the EIC of the endogenous peptide (MCF7-light) without any spike. The 
bottom EIC (Mix-heavy) shows the EIC of the SIS peptide in the SIS peptide mixture. The six 
EICs in between (0.05-light, 0.05-heavy, 1-light, 1-heavy, 20-light and 20-heavy) show EIC’s 
of the light and heavy (SIS) peptide from the three validation experiments, in which the MCF7 
tryptic digest was spiked with the SIS peptide mix at three different concentrations (0.05, 1 
and 20 fmol for every µg of tryptic digest). The EICs of the SIS peptide in the validation runs 




Figure 58.  Visualization of the RNA-seq data of MCF7 cells analyzed by TopHat and BWA. 
A significant number of reads (indicated by an oval), aligned by both TopHat and BWA, were 






We utilized customized protein sequence databases for the identification of non-canonical 
peptides in MCF7 cells. These were:- 
i) SNVs and Insertion/Deletion mutations identified in Exome-Seq, RNA-seq and 
publicly available through COSMIC were utilized for the identification of peptides 
from variant proteins.  
ii) Transcript sequences from GENCODE and RefSeq were utilized for discovering 
peptides from uORFs, dORFs, and alternate-reading-frame encoded proteins in 
protein coding genes.  
iii) Transcripts with biotypes “lncRNA” and “retained intron” from GENCODE were 
searched in three frame for the identification of peptides from non-coding 
transcripts.  
iv) Protein coding gene sequences and CDS sequences including flanking sequences 
of up to 100 base pairs were translated in three frames in order to identify peptides 
spanning exon-intron boundaries and introns.  
v) GNOMON predicted proteins were utilized for the identification of novel isoforms 
and variants that were not identified in Exome-seq and RNA-seq experiments.  
vi) A six-frame translation search of the transcriptome (GENCODE and RefSeq) and 
full human genome was also performed in order to identify peptides from novel 
coding DNA sequences. 
A reference proteome database was constructed by merging reference protein sequences from 
GENCODE, RefSeq and UniProt. We first performed extensive searches with the reference 
proteome database to identify all peptides that could be assigned to reference proteins. Thus, 
the results concern peptides that could not be assigned to a reference proteome.  
The analysis led to the identification of 1227 non-canonical peptides (Table 2 and online 
appendix 2) after an exhaustive quality control analysis of the MS/MS spectra and search 
engine identification results to ensure all non-canonical peptides originated from high quality 
spectra, and which could not be explained by known modifications. Specifically, 
i) Non-canonical peptides were removed if they differed from reference peptides by 
only Leucine/Isoleucine or deamidation;  
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ii) Non-canonical peptides were removed if they were only detected in a modified 
form;  
iii) Non-canonical peptides from ORFs, GNOMON, transcriptome and genome 
searches were accepted only if they possessed sufficient sequence diversity (at 
least 3 amino acid difference) from any peptide within the reference proteome 
database.  
iv) Non-canonical peptides were removed if their precursor ion isolation contained 
greater than 70% interference. 
v) Non-canonical peptides were removed if their MS/MS spectrum was 
characterized by a low number of peaks or low signal-to-noise. 
To validate the results and confirm the presence of the non-canonical peptides stable isotope-
labeled standard (SIS) peptides were synthesized and used as reference standards. We then 
followed a two-tier validation strategy. In tier 1 we quantified the similarity of the MS/MS 
spectrum of the endogenous peptide with that of its isotopically labeled reference standard 
(using only those fragment ions that could be assigned). Endogenous peptides with cosine 
similarity greater that 0.9 were considered validated at tier 1. For tier 2 validation we examined 
the extracted ion chromatogram of the tier 1 peptides. Peptides that eluted at identical elution 
times, and that had elution and isotopic profile similarities greater than 0.9 were considered 
validated at tier 2. 
  
 
4.1. Choice of reference proteomes can impact which proteoforms are identified  
The LC-MS/MS data was searched with all three common reference proteomes from 
GENCODE, UniProt and RefSeq. It was found that utilizing different reference proteome 
databases could impact which canonical protein isoforms were identified. For example, two 
peptides “GYATDESTVSSVQGSR”, and “EKGYATDESTVSSVQGSR” were identified 
from a predicted splice isoform (XP_005247870) of FMR1 autosomal homolog 1 (FXR1) in 
the RefSeq database. This predicted isoform is not present in the UniProt or GENCODE 
reference protein databases. The peptides spans the boundary of intron 12-13 (grey text above) 
and exon 13 (black text above) of the pre-mRNA transcript NM_005087.3 (Figure 59). The 
retention of intron 12-13 in the protein-coding transcript would cause the insertion of 28 amino 
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acids “MGFRPSSTRGPEKEKGYATDESTVSSVQ” at position 379 in the reference FXR1 
protein NP_005078.2. The splice isoform is predicted to be produced by RefSeq annotation 
but not by GENCODE. The RNA-seq data of MCF7 cells contains alignments at intron 12-13, 
and the proteogenomic analysis reported here identified the associated proteolytic peptide, 
indicating that this predicted splice isoform of FXR1 is expressed in MCF7 cells at the gene 




Figure 59. Visualization of the RNA-seq data of MCF7 cells analyzed by TopHat and BWA. 
RNA-seq reads aligned between exon 12 and exon 13 of FXR1 protein coding transcript 
NM_005087.3. A significant number of reads (black circle) aligned to intron 12. The identified 
peptides “GYATDESTVSSVQGSR” “EKGYATDESTVSSVQGSR” contain amino acids 
from intron 12 (grey amino acids) and exon 13 (black amino acids).  
 
 
4.2. Validation of peptides with missed cleavages  
Peptides with missed cleavages are not routinely utilized for validation because the digestion 
efficiency in different experiments may differ; furthermore it has been reported that missed 
cleavage peptides are detected with lower sensitivity 105. However, missed cleavage peptides 
span a larger fraction of a protein’s sequence, thereby enabling the identification of more 
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proteoforms. In our analysis we targeted peptides for validation that contained missed 
cleavages. The peptide “K.GTAAAAAAAAAAAAAKVPAKK.I”, with 2 missed cleavages, was 
identified in the proteogenomic discovery experiments with 3 extra Alanine residues (grey text 
above). The MS/MS spectra used to identify this peptide in the discovery experiments 
exhibited a high similarity (0.97) with the MS/MS spectrum of the SIS peptide standard (Figure 
32). However, we did not detect this missed cleavage peptide in the validation experiments 
presumably because of the increased digestion efficiency of the validation experiments 
(determined by calculating the proportion of missed cleavage peptides). The terminal tryptic 
peptide “K.GTAAAAAAAAAAAAAK.V” was detected in both the proteogenomic discovery 
and validation experiments but was omitted from the list of non-canonical peptides because 
the spectrum also matched a semi-tryptic peptide from the reference proteome, but with a lower 
score. As a conservative approach, we rejected all peptides whose spectra matched to peptides 
from the reference proteome. Although, we could not detect the endogenous missed cleavage 
peptide in the validation experiments the high similarity score in tier 1 validation indicates the 
proteoform is present in MCF7 cells.  
 
4.3. Variant missed in next-generation sequencing 
The variant calling programs used for the analysis of next-generation sequencing data reject 
mutations that do not meet a user-defined minimum number of reads. If a mutation does not 
generate sufficient reads they are rejected as artifacts. Or in other words, if the sequencing 
experiments are not performed with sufficient depth the exons on which the variant lies might 
not be sequenced, or the result deemed unreliable. We detected a total of 15 peptides from the 
GNOMON-small database that were classified as novel-isoform-pep and non-coding-pep but 
could be aligned to reference proteins by a single amino acid variation (online appendix 6). 
Accordingly, we considered if these peptides were variants that were not detected by NGS. Six 
of the peptides were targeted for validation, of which 5 passed tier 1 validation and 3 also 
passed tier 2 validation. The genomic coordinates of the peptides as undetected variants of 
reference proteins were obtained by utilizing the software tool PoGo 106 and are provided in 
online appendix 7. As an example, the peptide “K.AEEPGDGPAEEWLGR.A” was identified 
from the GNOMOM protein model of SFT2 domain containing 3 (SFT2D3) but with the 
Arginine (R) at position 38 replaced by a Glycine (G) (shown in grey for clarity). This peptide 
 112 
was successfully validated at tier 1 and tier 2 (Figure 60 and Figure 61). A longer missed 
cleavage peptide, “K.AGGPAAAEPLLAAEKAEEPGDGPAEEWLGR.A”, was also 
identified but was too long for our provider of stable isotope-labeled standard peptides, and so 
could not be validated.  
Figure 62 shows the mapping of these 2 peptides onto the SFT2D3 gene on the alternate 
assembly. Close examination of the dbSNP database revealed a missense variant “rs10206957” 
that would cause this amino acid substitution. SFT2D3 is an intronless gene on chromosome 
2. The variant was not detected in the NGS experiments due to absence of read coverage in the 
CDS region of the gene (Figure 63).  
  
   
 
Figure 60. Annotated MS/MS spectra of the endogenous (top left) and SIS peptide (bottom 
left) from an undetected variant of SFT2D3. Peptide “K.AEEPGDGPAEEWLGR.A”, charge 
2+. The N-terminal (a/b) and C-terminal (y) fragment ions are shown in red, internal fragments 
(a-type, b-type) in green and un-fragmented precursors in orange. Ammonia loss is shown with 
a * and water loss is shown with a $ sign. The spectra on the right show the MS/MS peaks 
selected for the similarity computation (top: endogenous peptide, bottom: SIS peptide). The 
intensities of the selected peaks were variance stabilized by square root transform and 
normalized to sum 1000 before similarity computation. The intensities of 36 common 





Figure 61. Extracted ion chromatograms (EIC) of endogenous and SIS peptides from an 
undetected variant of SFT2D3 gene from five validation runs. Peptide 
“K.AEEPGDGPAEEWLGR.A”, charge 2+. The elution profiles were compared within the 
time window highlighted with a light blue box. The peptide passed tier 2 validation with a 
profile similarity of 0.98. Apex elution times for the SIS and endogenous peptides were 
identical in all validation runs. The MS/MS identification time points are shown with black 
vertical lines. Asterisks (*) indicate the MS/MS spectra have also been validated at tier 1 with 
a cosine similarity above 0.9.The top EIC (MCF7-light) shows the EIC of the endogenous 
peptide (MCF7-light) without any spike. The bottom EIC (Mix-heavy) shows the EIC of the 
SIS peptide in the SIS peptide mixture. The six EICs in between (0.05-light, 0.05-heavy, 1-
light, 1-heavy, 20-light and 20-heavy) show EIC’s of the light and heavy (SIS) peptide from 
the three validation experiments, in which the MCF7 tryptic digest was spiked with the SIS 
peptide mix at three different concentrations (0.05, 1 and 20 fmol for every µg of tryptic 
digest). The EICs of the SIS peptide in the validation runs are inverted for ease of comparison 







Figure 62. Peptide evidence for the SFT2D3 protein from the alternate genome assembly 
CHM1_1.1. The two peptides “K.AEEPGDGPAEEWLGR.A” and 
“K.AGGPAAAEPLLAAEKAEEPGDGPAEEWLGR.A” map onto the SFT2D3 gene. 
Nucleic acid at chromosome location chr2:128463821 on the alternate assembly is Guanine 
(G) whereas it is Cytosine (C) in the reference assembly (GRCh38) for transcript 
NM_032740.3. This nucleic acid change would cause the amino acid Arginine (R) at position 
38 on the reference assembly protein NP_116129.3 to be replaced by Glycine (G), as was 
detected here (shown with grey text above). Green bars denote reference genes. Purple bars 
denote reference transcripts, and red bars reference proteins. The location of the peptide 





Figure 63. Low read coverage in the coding DNA sequence (CDS) of SFT2D3. Significant 
reads were aligned in the 3’-UTR region of SFT2D3 but almost no reads aligned with the CDS 




Two peptides “K.NSVTPDM-EEMYKK.A” and “K.NSVTPDM-EEMYK.K” were identified 
from GNOMON predicted protein of 60S ribosomal protein L5 (RPL5) gene, in which the 
methionine (M) at position 236 on reference protein ENSP00000495549 is deleted (shown 
with a hyphen above). The peptide “K.NSVTPDM-EEMYK.K” was validated at tier 1 and 2 
(Figure 64 and Figure 65). An examination of the dbSNP database did not reveal any deletion 
variants at this position. The peptides span the boundary of exon 6 and exon 7 on transcript 
ENST00000644759, indicated with black and grey text above. The RNA-seq intron features 
from NCBI show that transcripts with both consensus (GT-AG) and non-consensus (GT-TG) 
splice sites have been reported at the junction of exons 6 and 7 in RPL5 (Figure 66). The 
canonical splicing encodes the reference RPL5 protein whereas the alternate splicing would 
cause the skipping of Methionine at position 236.  
 
 
Figure 64. Annotated MS/MS spectra of the endogenous (top left) and SIS peptide (bottom 
left) from the GNOMON predicted protein of RPL5. Peptide “K.NSVTPDM-EEMYK.K”, 
charge 2+. The N-terminal (a/b) and C-terminal (y) fragment ions are shown in red, internal 
fragments (a-type, b-type) in green and un-fragmented precursors in orange. Ammonia loss is 
shown with a * and water loss is shown with a $ sign. The spectra on the right show the MS/MS 
peaks selected for the similarity computation (top: endogenous peptide, bottom: SIS peptide). 
The intensities of the selected peaks were variance stabilized by square root transform and 
normalized to sum 1000 before similarity computation. The intensities of 31 common 





Figure 65. Extracted ion chromatograms (EIC) of endogenous and isotopically-labeled 
standard peptides from the GNOMON predicted protein of RPL5 gene in five validation runs. 
Peptide “K.NSVTPDM-EEMYK.K”, charge 2+. The elution profiles were compared within 
the time window highlighted with a light blue box. The peptide passed tier 2 validation with a 
profile similarity of 0.97. Apex elution times for the SIS and endogenous peptides were nearly 
identical in all validation runs. The MS/MS identification time points are shown with black 
vertical lines. Asterisks (*) indicate the MS/MS spectra have also been validated at tier 1 with 
a cosine similarity above 0.9. The top EIC (MCF7-light) shows the EIC of the endogenous 
peptide (MCF7-light) without any spike. The bottom EIC (Mix-heavy) shows the EIC of the 
SIS peptide in the SIS peptide mixture. The six EICs in between (0.05-light, 0.05-heavy, 1-
light, 1-heavy, 20-light and 20-heavy) show EIC’s of the light and heavy (SIS) peptide from 
the three validation experiments, in which the MCF7 tryptic digest was spiked with the SIS 
peptide mix at three different concentrations (0.05, 1 and 20 fmol for every µg of tryptic 
digest). The EICs of the SIS peptide in the validation runs are inverted for ease of comparison 





Figure 66. Peptide evidence of alternative splicing in RPL5. Visualization of two peptides 
“K.NSVTPDM-EEMYKK.A” and “K.NSVTPDM-EEMYK.K” on the RPL5 gene, Ensembl 
id: ENSG00000122406. The NCBI reference transcripts (shown in purple) with the canonical 
splicing GT-AG (black arrow line) would lead to the generation of the canonical protein 
sequence (with methionine), whereas the alternate splicing GT-TG (orange arrow line) would 
lead to the detected protein, without methionine at position 236. Green bars denote reference 
genes. Purple bars denote reference transcripts, and red bars reference proteins. Colored blocks 
represent exons, and lines introns. The genomic locations of the peptides are shown in the 
bottom track (short dark grey blocks at the beginning and end of the light grey block (intron), 
and overlapping with the exons). 
 
 
4.4. Ambiguous proteogenomics peptides 
A total of 65 non-canonical peptides were classified as ambiguous (Table 2). For example, the 
non-canonical peptide “R.CHLGPGHQAGPGLHRPPSPR.C” was identified with 2 PSMs 
from protein coding transcript ENST00000611571 of Mucin 1 (MUC1) in a non-canonical 
frame (Figure 67). Proteogenomic mapping revealed the peptide could be mapped onto 22 
genomic co-ordinates, all within the MUC1 mRNA (Figure 68). The peptide is classified as 
ambiguous due to multiple coordinate hits on the transcriptome but it is produced 
unambiguously by the MUC1 gene.  
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Figure 67. MS/MS spectra of peptide “R.CHLGPGHQAGPGLHRPPSPR.C”, charge 5+, m/z 
426.42. The noise level (blue horizontal line) was determined by DNL. The N-terminal (a/b) 
and C-terminal (y) fragment ions are shown in red, internal fragments are shown in green and 
un-fragmented precursors in orange. Ammonia loss is shown with a * sign and water loss is 





Figure 68. Ambiguous mapping of a peptide. The peptide “CHLGPGHQAGPGLHRPPSPR” 





Some non-canonical peptides could be classified into different classes if different genome 
annotation systems were used. Peptide “R.VDPQGQCPEHGACPSLLAHVSAEGR.R” was 
identified with a single PSM from the HELZ2 gene (Figure 69). Proteogenomic mapping 
revealed that the peptide has a unique coordinate within the HELZ2 gene (Figure 70). 
However, the peptide is classified as ambiguous because it could be mapped onto two non-
coding transcripts of HELZ2 from GENCODE with different biotypes; ENST00000370082 - 
“retained intron” and ENST00000479540 - “processed transcript”. Note: The GENCODE 
annotation was preferentially used over NCBI; if the NCBI annotation was given priority the 
peptide would have been unambiguously classified as an uORF-peptide because it maps onto 
the 5’-UTR region of RefSeq protein coding transcripts NM_001037335, XM_024452007 and 
XM_024452006 (Figure 70). Utilizing NCBI annotation over GENCODE would cause some 
proteogenomic peptides to be classified differently due to the differences in the transcript and 




Figure 69. MS/MS spectra of peptide “R.VDPQGQCPEHGACPSLLAHVSAEGR.R”, charge 
4+, m/z 668.81. The noise level (blue horizontal line) was determined by DNL. The N-terminal 
(a/b) and C-terminal (y) fragment ions are shown in red, internal fragments are shown in green 
and non-fragmented precursors in orange. Ammonia loss is shown with a * sign and water loss 




Figure 70. Mapping of “R.VDPQGQCPEHGACPSLLAHVSAEGR.R” onto HELZ2 is 
dependent on which annotation system is used (Ensembl or NCBI). The peptide maps onto two 
Ensembl transcripts ENST00000479540 and ENST00000370082 with biotypes “processed 
transcript” and “retained intron”, respectively. Based on NCBI RefSeq annotation the peptide 
maps onto the 5’-UTR region of protein coding transcripts NM_001037335, XM_024452007 
and XM_024452006. Green bars denote reference genes. Purple bars denote reference 
transcripts, and red bars reference proteins. Colored blocks represent exons, and lines introns. 
The location of the non-canonical peptides identified by the proteogenomic search is shown in 
the bottom row.   
 
 
4.5. Unmapped proteogenomics peptides 
A total of 55 peptides were classified as unmapped in our analysis (Table 2). Unmapped 
peptides were identified in searches conducted with CDS extensions, 6 frame transcriptome 
and GNOMON databases. Some peptides remained unmapped due to differences between the 
annotations of the genomic features utilized to generate the databases (GENCODE version 25) 
and the one used to map them (GENCODE version 27). Most unmapped peptides either had a 
stop codon replaced with a standard amino acid or were produced from the N-term/C-terminal 
of the ORFs from CDS extension databases. During database search with Mascot (version 2.5) 
stop codons in nucleic acid searches and unknown amino acids (X) in amino acid searches are 
replaced by all standard amino acids. Peptides identified from these databases may have a stop 
codon or unknown amino acid replaced by a standard amino acid. We considered such peptide 




4.6. Novel proteoforms are expressed in MCF7 cells 
We successfully validated the protein level expression of variants identified in next-generation 
sequencing. Our analysis demonstrated that besides SNVs many other proteoforms could be 
detected in MCF7 cells. Peptide “K.AGGAADMTDNIPLQPVR.Q” was identified from the 
uORF of ATP9A mRNA. Expression of uORFs have been shown to regulate the expression of 
main ORF genes 50. The peptide “R.GLQLLQPHQLLQGR.G” was validated from the last 
exon of the KRT8 gene in a non-canonical frame. An undetected frame-shift or ribosomal 
frame-shifting may be responsible for the production of the resulting truncated KRT8 protein 
in MCF7 cells. KRT8 is the major component of intermediate filament cytoskeleton and its 
high expression has been linked to tumor progression and metastasis of gastric cancer 107. 
KRT8 expression is enhanced in MCF7 cell lines  108. 
 
A peptide “R.GAEVPGEAAPGAR.A” was validated from the long non-coding RNA gene 
GATA3-AS1. The peptide was identified from an ORF of length 125 amino acids within the 
GATA3-AS1 gene (Figure 71). The translation of GATA3-AS1 in MCF7 cells is particularly 
interesting because the gene coding for the protein GATA3 is on the opposite strand and 
harbors an insertion mutation that leads to the translation of a truncated proteoform of GATA3 
41. Recent evidence demonstrates that peptides produced from long non-coding RNA genes 
can have important biological and functional roles, for example the small peptide Myoregulin 











We validated multiple peptides from an N-terminally extended novel isoform of STARD10 
protein (Figure 72). STARD10 protein is over-expressed in breast cancer 109 and the MCF7 
breast cancer cell line used here110,111.  STARD10 functions as a phospholipid transporter, and 
a loss of expression has been reported as indicative of poor prognosis 112.  The 77 amino acid 










Figure 72. Peptides detected from a GNOMON predicted N-terminal extended isoform of 
STARD10. The N-terminal extended part is shown in black and the reference STARD10 
protein is shown in grey. The 6 non-canonical peptides identified by the proteogenomics 
search, namely “MEEELALGPR.G”, “R.SAGAGSYGALANSAWGGPR.K”, 
“R.SAGAGSYGALANSAWGGPRK.V”, “R.KVASASAAASTLSEPPR.R”, 
“R.KVASASAAASTLSEPPRR.T”, and “K.VASASAAASTLSEPPR.R”, were all identified 
from the extended N-terminal region (peptides underlined for clarity).  
  
 
The peptide “R.SPPDSPTDALMQLAK.A” mapped onto a novel exon situated between exons 
17 and 18 in the gene TLN1. This isoform of TLN1 gene has 17 amino acids 
“ICASRGAGVRSPPDSPT” coded by the novel exon, which is inserted at amino acid position 
666 in the reference TL1 protein. TLN1 codes for a cytoskeletal protein that is concentrated in 
areas of cell-substratum and cell-cell contacts 113,114.  
The peptide “K.NSVTPDM-EEMYK.K” was validated from an isoform of the protein RPL5 
due to non-canonical splicing of exon 6 and 7. The variant was not detected in NGS 
experiments but was identified from the GNOMON database. The splicing caused deletion of 
a methionine residue at the start of exon 7. RPL5 protein is a component of the large ribosomal 
subunit. Mutations in RPL5 have been associated with defects in the maturation of ribosomal 
RNAs in the small or large ribosomal subunit production pathways 115.  
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The peptide “R.ASAAEGVGEPGASAGR.A” was validated from an upstream extension of 
exon 1 within the gene WDR26. The peptide spans the boundary of 5’-UTR and the genomic 
region upstream of 5’-UTR, suggesting the expression of a novel CDS in this region. The 
protein belongs to the WD repeat protein family, and is involved in a variety of cellular 
processes including cell cycle progression, signal transduction, apoptosis and gene regulation 
116,117 . It has been shown that WDR26 is overexpressed in highly malignant breast cancers and 
has been proposed as a potential therapeutic target for breast cancer 118.  
We performed a comprehensive proteogenomics analysis of MCF7 cells with customized 
protein sequence database searches. In addition to confirming the protein forms of variants 
identified by next-generation sequencing, multiple novel proteoforms were also validated. 
Bottom-up LC-MS/MS is widely used for profiling of proteomic landscape of complex 
biological samples. It is well known that a large proportion of the acquired spectra in LC-
MS/MS experiments cannot be assigned. Some of these spectra remain unassigned due to 
absence of the proteoforms in the compact reference proteome databases utilized in proteomics 
data analysis pipelines. Our results demonstrates that a subset of these unassigned spectra 
originate from genomic mutations and pervasive translations from outside of the known protein 
coding regions of the genome. The results demonstrated how the reference databases 
commonly utilized in proteomics workflows do not fully capture the complexity of the 
oncoproteome space, and if possible should be supplemented with sample specific variant and 
novel proteoforms.  
 
5. Conclusions 
In this work I have developed a comprehensive proteogenomics identification and validation 
pipeline. The pipeline was utilized to discover and validate proteogenomics peptides in MCF7 
cells (Figure 73). I used the Python programming language to develop scripts for: construction 
of customized databases, noise-detection in MS/MS spectra, comprehensive annotation of 
matched MS/MS spectra, proteogenomic mapping of all classes of peptides, and the 
quantitative comparison of endogenous non-canonical peptides with their isotopically labeled 
analogues (SIS peptides).  
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Figure 73. Proteogenomics analysis and validation pipeline. 
 
First several customize databases were generated and used to analyze the LC-MS/MS data to 
discover novel proteoforms. Variants detected in Exome-seq, RNA-seq and publicly available 
in COSMIC were utilized to identify SNVs and InDel peptides. Exon-skipped peptides were 
identified by generating a database of novel exon-skipped proteins from reference transcripts. 
Peptides from uORFs, dORFs and alt-frame translations were identified using a database of 
ORFs generated from a reference transcriptome. Peptides spanning exon-intron boundaries 
were identified using a database of ORFs generated from 100 base-pair extensions of CDS and 
gene sequences. Peptides from non-coding transcripts were identified using a database of ORFs 
generated from non-coding transcript sequences. Peptides from novel protein isoforms were 
identified using a database of Gnomon proteins.  
The LC-MS/MS data was first interrogated with all common reference proteomes from 
UniProt, GENCODE and RefSeq. I demonstrated that the choice of reference proteome 
database can affect the identification of non-canonical peptides. This problem was avoided by 
utilizing non-redundant protein sequences from all common reference proteomes. A merged 
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reference proteome database was created incorporating the reference proteomes in UniProt, 
GENCODE and RefSeq.   
Peptides that were identified exclusively from the proteogenomics searches were subjected to 
rigorous quality control. First I applied a noise detection algorithm to filter out PSMs whose 
MS/MS spectra were of low signal-to-noise, and which did not contain sufficient signal peaks. 
Then, I developed a spectrum annotation tool to ensure the non-canonical peptides could 
account for the majority of fragment ions contained in their MS/MS spectra. These QC steps 
ensured all reported non-canonical peptides were identified using high quality MS/MS spectra 
that could describe the full MS/MS spectrum, and thus reduced the likelihood of false-positive 
identifications.  
I performed genomic mapping of the QC controlled peptides. I was able to successfully map 
all classes of peptides to their genomic co-ordinates. I assigned a genomic context to the 
peptide based on their mapping which was later used for their classification.  
Finally I validated many of the non-canonical peptides with SIS peptides. I developed a two 
tier validation scheme: in tier 1 I compared the fragmentation pattern of endogenous and SIS 
peptides. Peptides that had a similarity score greater than 0.9 were subjected to tier 2 validation, 
in which I compared their elution profiles. To guard against co-eluting ions, profile similarity 
was also computed for each peptide isotope (monoisotopic, 1C13 and 
2C13). Peptides that had 
elution profile similarity and isotopic composition similarity greater than 0.9 were considered 
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